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Protein misfolding as a result of polyglutamine (polyQ) repeat expansion plays a crucial role in 
the development a class of neurodegenerative disorders. These disorders are characterized by 
expansions in unique proteins, but share one common factor: polyQ repeat expansions beyond a 
pathological threshold, usually near 35 Glns. PolyQ containing peptides and proteins aggregate 
into amyloid-like fibrils, in both disease states and in vitro. While recent studies of simple polyQ 
aggregation have led to the development of a mechanism describing the fibril formation 
pathway, the kinetic and thermodynamic roles of even small modifications to the amino acid 
sequence are unclear. The goal of this work was to gain more specific information regarding the 
biophysical roles of terminal charge and Gln repeat length in the aggregation mechanism of 
simple polyQ peptides. We found that increases in both repeat length and attraction between 
terminal flanking sequences led to enhancements in fibril stability and spontaneous aggregation 
ability. In general, mutations in polyQ sequences that enhance their ability to assume a β-hairpin 
structure (the proposed building block of polyQ fibrils), and to associate with each other 
facilitate fibrillization through a nucleated polymerization pathway with a monomeric nucleus. 
The data discussed here have made significant contributions to our understanding of the basic 
aggregation properties of polyQ peptides, and have implications that can be directly translated to 
polyQ disease pathogenesis. 
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1.0  INTRODUCTION 
1.1 AMYLOID FIBRILS 
1.1.1 Amyloid Structure and Properties 
The ability to polymerize and form amyloid fibrils is a characteristic that seems to be inherent to 
the nature of polypeptide chains [1-5]. Misfolding and aggregation of specific cellular proteins is 
an important causative factor in a number of serious diseases, over 20 of which are characterized 
by the formation of amyloid fibrils [3, 6]. In spite of their implication in disease, formation of 
amyloid fibrils in vivo has also been suggested to sometimes play a functional or protective role 
[7-9].  
Amyloid fibrils can be identified by their fibrillar morphology (as observed by electron 
microscopy (EM) or atomic force microscopy (AFM)), enhancement of thioflavin-T (ThT) 
fluorescence upon binding, and their birefringence in polarized microscopy as enhanced by 
Congo red staining [3, 10]. They also share a set of common structural attributes, in spite of the 
fact that each disease is characterized by aggregation of a particular protein. The most notable 
feature of amyloid fibrils is that they are made up primarily of cross-β sheet, as identified via the 
cross-β x-ray diffraction pattern of aligned fibrils [3]. In cross-β sheet, β-strands lie orthogonal to 
the fibril axis and assemble into β-sheet via backbone H-bonds that run parallel to the fibril axis. 
 2 
Sheet-sheet packing is stabilized through side-chain interactions perpendicular to the fibril axis 
[11]. Most fibrils consist of parallel, in-register β-sheet, though some fibrils have been found to 
consist of pseudo-in register parallel strands, and only rarely (polyQ fibrils) are anti-parallel 
sheets observed [12].  
 
Figure 1-1. β-arcade structures. 
A β-hairpin (A), consists of two β-strands of at least 7 or 8 residues each linked by a turn or loop. This structure is 
stabilized predominantly through main-chain—main chain hydrogen bonding (orange dashed lines). The β-arch (B), 
is similarly made up of two β-strands linked by a turn. In this case, the structure is primarily formed by 
intramolecular side chain interactions and stabilized as additional molecules bind, establishing intermolecular main 
chain hydrogen bonds. 
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Except for fibrils formed by very short peptides, amyloid fibrils nearly always comprise 
of a series of β-strands linked by turns and/or loops [13-15]. The β-arch is commonly observed in 
amyloid, and has been identified as the building block of a number of fibrils, including amyloid-
β (Aβ) and yeast prion proteins [14]. In this structure, intrachain β-strands stack on top of each 
other, linked by a large turn or loop (Figure 1-1 B). The β-arch is stabilized by intramolecular 
side chain interactions and intermolecular main-chain hydrogen bonds that form as additional 
molecules bind. The antiparallel or parallel nature of the growing β-sheet is determined by the 
orientation of elongating molecules. β-hairpins (Figure 1-1 A) consist of a pair of β-strands 
aligned side-by-side and linked by a turn or loop, forming a two strand antiparallel sheet 
stabilized by intramolecular main-chain hydrogen bonds. [16, 17]. β-hairpins are uncommon in 
amyloids described to date, but have been proposed as building blocks of the antiparallel β-sheet 
containing polyQ fibrils (described in more detail in section 1.3.2) [18-20].  
1.1.2 Amyloid Aggregation 
In the most general sense, formation of amyloid fibrils is a protein misfolding reaction. More 
specifically, however, there are a number of possible mechanisms by which a single protein or 
peptide can become a part the highly-structured complex that is an amyloid fibril (Figure 1-2).  
It is generally accepted that amyloid formation entails a number of features of a nucleated 
growth polymerization mechanism, wherein a structural nucleus is formed, followed by rapid 
association of additional molecules resulting in formation of the amyloid fibril. The particular 
nature of the nucleus (monomeric vs. multimeric, its exact structure, etc.) and mechanism of 
elongation (monomer addition vs. association of oligomers or complexes) vary from peptide to 
peptide. 
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While a primary nucleus serves as the catalyst to promote amyloid formation, fibrils are 
also capable of secondary nucleation via fragmentation of the fibril or branching [21, 22]. When 
this occurs, new, previously inaccessible growing ends are presented to the reaction. Kinetic 
contributions from secondary nucleation events make it nearly impossible to extract information 
about primary nucleation from the aggregation kinetics [22-24]. Because of this, systems which 
do not undergo secondary nucleation as a part of their polymerization mechanisms provide ideal 
opportunities to glean information about the primary nucleation phase of the aggregation 
mechanism.  
Once nucleation occurs, the polymerization process proceeds by addition of molecules 
(whether by monomer addition or otherwise) to the growing ends of the fibril, and continues 
until an equilibrium is reached. At this point, the monomer concentration stabilizes at a value 
referred to as the critical concentration (Cr). Cr can be regarded as an indication of the stability of 
the fibril, and corresponds to the inverse association constant for fibril growth (Ka-1). Thus, the 
Cr can be used identically to Ka-1 to calculate the free energy of elongation, ΔGelong= -RT ln 
(1/Cr). This approach has been validated with Ala scanning mutations in Aβ(1-40) [25]. The Cr 
values of a series of Ala mutations were used to determine ΔGelong values, which, in turn, were 
used to calculate the ΔΔGelong values for each mutation by comparing to the wild-type ΔGelong 
value (ΔΔGelong = ΔGelongWT - ΔGelongMut). When matched to analogous mutations at adjacent 
positions in parallel β-sheet in the globular GB1 protein, these ΔΔG values showed good 
agreement, indicating that the use of Cr values to determine ΔGelong is a robust approach to 
measure fibril stability in comparative studies. 
In a number of cases, oligomeric species have been identified as intermediates to amyloid 
formation [21, 26-28]. The increased interest in these oligomeric species has been driven by their 
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proposed role as the toxic species in amyloidosis [29, 30]. Some of these oligomers appear to be 
on-pathway intermediates, such that when they are isolated and used as seeds, amyloid formation 
is accelerated [27, 31], but this is not always the case [32]. In the Aβ system, although many non-
fibrillar assemblies have been identified, most oligomers can be labeled as one of two key types: 
soluble oligomers that are low in molecular weight and disorganized in structure, or chain-like 
structures with diameters of 2-5 nm that are rich in β-sheet (observed via EM and AFM) [28, 33]. 
It is this second species of oligomer, referred to as a protofibril, that appears to be an on-pathway 
intermediate of amyloid formation (Figure 1-2). The smaller, soluble oligomers, have been 
observed in in vivo studies and are believed to play a toxic role in disease pathogenesis [29].  
Elongation of amyloid fibrils is a more complex process than the simple association of 
incoming molecules to the growing end of the fibril. Elongation can occur via monomer addition, 
or by assembly of oligomers or protofibrils [27, 34]. Even in the case of monomer addition, the 
newly bound monomer must undergo conformational changes in order to become stably 
incorporated and present a new growing end to the system. Thus, fibril elongation is believed to 
be a multi-step process, wherein the elongating monomer adds via a “dock and lock” mechanism 
[35, 36]. The “docking” phase occurs when a disordered monomer encounters and binds to the 
growing end of a fibril (or nucleus). It is followed by one or more “locking” steps, in which the 
molecule adding to the fibril folds, assuming the β-sheet rich structure that is capable of 
supporting subsequent growth. Surface plasmon resonance (SPR) studies of the Aβ peptide 
revealed that it elongates via a 3 step mechanism, with two kinetically defined “locking” steps 
[35]. The six individual elongation and dissociation rates measured during this study could be 
propagated into an overall equilibrium constant which corresponds very well to the 
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independently determined Ka value for Aβ determined from Cr [37] (further validating the use of 
the Cr value as a measure of fibril stability). 
 
Figure 1-2. Amyloid formation occurs via a complex pathway. 
From [30]. 
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In summary, amyloid fibril formation is a complex process, during which a single 
molecule undergoes a series of conformational changes as it proceeds toward its ultimate fibrillar 
state [30]. As with any protein folding reaction, an unfolded molecule samples a number of states 
as it folds, some of which may involve association with other molecules into oligomers or higher 
order aggregates (Figure 1-2). In some cases, the formation of these complexes is on-pathway, 
with oligomers capable of acting as fibril nuclei or elongation material. In other cases these 
oligomers are off-pathway, forming structures not directly related to the fibril and whose only 
role is to tie up molecules and at least transiently prevent their involvement in the aggregation 
reaction. In the simplest case, disordered monomer is capable of undergoing a conformational 
change to nucleate amyloid formation and elongate via monomer addition. This process is 
discussed in more detail in Section 1.3.5.1. 
1.2 POLYGLUTAMINE REPEAT DISORDERS 
1.2.1 General features 
Trinucleotide repeat expansions have been implicated in more than 16 neurodegenerative 
diseases [38-40]. CAG repeat disorders are a disease family characterized by the expansion of 
CAG nucleotides. When repeats of this codon occur in coding regions of the genome, the result 
is a polyQ expansion, which has been linked to 10 of the more than 20 amyloidoses (Table 1) [3, 
4, 30, 41, 42]. While the focus of this work is on the polyQ containing polypeptides resulting 
from expressed CAG repeat containing DNA [43], some diseases are associated with 
trinucleotide expansions in non-coding regions of the genome. One disorder, HD-like-2, was 
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originally believed to fall into this group, since the CAG repeat expansion occurs in an anti-sense 
portion of DNA. However, the anti-sense strand is transcribed and translated, resulting in a 
protein product which has been implicated in a HD-like-2 [42, 44]. Because of the common 
features shared among these diseases, it is generally accepted that the polyQ containing protein is 
the key player in disease [41]. More specifically, neuronal toxicity has been proposed to be a 
result of a gain of function caused by expansion of the polyQ tract [40, 45, 46]. 
Table 1-1. PolyQ Repeat Disorders 
Disease Protein Normal Repeat 
Length 
Expanded 
Repeat Length 
Clinical Features 
Huntington’s Disease (HD) Huntingtin (exon 
1) 
6-34 36-121 Chorea, dystonia, 
cognitive deficits, 
psychiatric problems 
Spinocerebellar ataxia 1 
(SCA1) 
Ataxin 1 6-44 39-82 Ataxia, slurred 
speech, spasticity, 
cognitive impairments 
SCA2 Ataxin 2 15-24 32-200 Ataxia, 
polyneuropathy, 
decreased reflexes, 
infantile variant with 
retinopathy 
SCA3 Ataxin 3 13-36 61-84 Ataxia, parkinsonism, 
spasticity 
SCA6 CACNA1A 4-19 10-33 Ataxia, dysarthria, 
nystagmus, tremors 
SCA7 Ataxin 7 4-35 37-306 Ataxia, blindness, 
cardiac failure in 
infantile form 
SCA17 TATA-binding 
protein (TBP) 
25-42 47-63 Ataxia, cognitive 
decline, seizures, and 
psychiatric problems 
Spinobulbar muscular 
atrophy (SBMA: Kennedy 
Disease) 
Androgen receptor 9-36 38-62 Motor weakness, 
swallowing, 
gynecomastia, 
decreased fertility 
Dentatorubropallidoluysian 
atrophy (DRPLA) 
Atrophin 7-34 49-88 Ataxia, seizures, 
choreoathetosis, 
dementia 
HD-like 2 * 7-27 40-60 abnormal movements, 
dementia, and 
psychiatric 
syndromes. 
Modified from [40], supplemented with [44]. * Since this disease protein results from translation from an anti-sense 
DNA strand, it does not correspond to a normally expressed protein. The sense strand, which codes for a CAG 
repeat, however, produces Junctophilin-3 (exon 2A). 
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The critical Gln repeat length threshold for amyloid in disease tends to lie in the mid-
thirties, with most diseases only manifesting symptoms when repeat lengths reach 35-45 Gln 
residues [41]. In some cases, such as spinocerebellar ataxia 6 (SCA6), the physiological repeat 
length threshold is much shorter, at approximately 16 to 20 Gln residues [47, 48]. This difference 
in repeat length threshold is possibly due to differences in sequence context, an idea that will be 
discussed in more detail below (1.2.2). As the Gln repeat length surpasses the threshold at which 
disease symptoms manifest, age of onset decreases. In the extreme case, very long polyQ repeats 
lead to highly aggressive juvenile forms of the disease (Figure 1-3) [41, 49, 50].  
The 10 proteins implicated in polyQ disorders range in size from 339 to 3144 residues 
(normal length). Their functionality is either unknown, or widely varies, as does their 
localization within the cell— the TATA-binding protein (implicated in SCA17) is localized to 
the nucleus and plays a role in transcription. CACNA1A (implicated in SCA6) is the α1A subunit 
of a voltage-gated calcium channel, and has only been observed to function in the cytoplasm. 
The androgen receptor containing the polyQ expansion associated with SMBA is a ligand 
activated transcription factor, found in the cytoplasm of neurons and the nuclei of non-neuronal 
tissue. 
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Figure 1-3. Age of disease onset is dependent on PolyQ repeat length. 
The average age of onset for a given repeat length is indicated by a (+). An exponential decay best fit is given by 
smooth lines. SCA6 clearly presents at the shortest repeat lengths, with most other diseases first manifesting at Gln 
repeat counts near 40.  Filled circles indicate patients homozygous for a polyQ expansion, while crosses are 
heterozygotes. Modified from [50]. 
The sequence context and location of the polyQ tract vary widely from protein to protein. 
These and other characteristics of polyQ proteins are listed in Table 1-2. Of particular interest is 
the fact that, in several of these proteins, polyQ repeat expansions are flanked by Pro rich 
regions. It has been suggested that these Pro containing regions exist to modulate the effects of 
the polyQ region by inducing formation of PPII helices [51, 52]. The effects of poly-Pro regions 
have been well studied in vitro and are discussed in more detail later in this chapter (1.3.3.2). 
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Table 1-2. PolyQ Protein Features1. 
Protein Protein Size 
(number of amino 
acids) 
Q Expansion Start 
Location 
N-terminal 
Charge/Features 
C-terminal 
Charge/Features 
Huntingtin 3144 18 +1 -65/Poly-Pro 
adjacent to polyQ 
region 
Ataxin 1 816 197 +3/Pro, Gly, Ala, 
Ser make up >40%, 
His interrupt polyQ 
+1/Pro and Ser rich 
Ataxin 2 1313 166 +18/Pro content 
>20%, Gly, Ala, Ser 
rich 
+30/poly-Pro 
adjacent to polyQ 
Ataxin 3 359 292 -21/Gln, Leu make 
up >20% 
-2/Ser, Leu make up 
>20% 
CACNA1A 2410 2328 +23/poly-Pro 
adjacent to polyQ 
+9/Ala, Arg, Gly, 
Pro, Ser make up 
>50% 
Ataxin 7 893 30 +1/Ala rich +47/poly-Pro 
adjacent to polyQ, 
rich in Ser and Pro 
TBP 339 58 -2/Gln and Pro rich +15 
Androgen receptor 918 58 +3/polyLeu adjacent 
to polyQ 
-14/short polyQ 
repeats 
Atrophin 1184 474 +5/Pro, Ser rich, His 
repeats adjacent to 
polyQ 
+4/Ala, Pro, Ser 
rich, His repeats 
adjacent to polyQ 
1.2.2 Role of Context in PolyQ Containing Proteins 
The differences in repeat length dependence of disease onset across polyQ disorders (i.e. SCA6) 
suggest the specific protein containing the polyQ expansion could play an integral role in disease 
manifestation. Context dependence of these disorders is further supported by characteristic 
neuronal degeneration patterns unique to each disease [53, 54]. Modifications to flanking 
sequences have been found to play meaningful roles in toxicity and disease progression [55]. For 
                                                 
1 All sequence information was acquired via UniProt for the human sequence of the particular protein. A 
sequence was called rich in a given amino acid if it was present in an amount ≥10%. 
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example, post translational modifications to flanking sequences in SCA1 and huntingtin exon 1 
have notable effects on toxicity in disease models [56-59], as well as on aggregation propensity 
in vitro [60]. These data indicate that toxicity and disease pathogenesis is controlled by polyQ 
containing proteins as a whole, rather than solely through the polyQ containing region. 
1.2.3 Physiological Features of PolyQ Disorders 
Despite the fact that polyQ diseases are caused by Gln expansions within entirely unique 
proteins, they each demonstrate similar pathogenic presentations. All polyQ disorders result in 
neuronal dysfunction and localized neuronal degeneration, in spite of ubiquitous expression of 
these proteins [43]. The unique neurodegeneration patterns within each disease are likely partly 
due to expression levels and cellular response to the presence of these proteins and their 
misfolding—lower expression levels and the presence of cellular machinery capable of 
regulating misfolded proteins have been found to correspond to decreases in neurodegeneration 
[41]—in addition to their sequence context, as mentioned above (1.2.2).  
 Neurological aggregates are observed in all polyQ disorders. These aggregates have been 
described as amyloid, or amyloid-like [61-63], and in vitro studies of polyQ containing peptides 
have been found to generate amyloid fibrils that have similar properties to the aggregates found 
in vivo [62, 64]. Additionally, aggregate formation has been demonstrated to have a similar 
repeat dependence as disease onset (discussed below, 1.3.4) [18, 65]. Because of the common 
features in disease pathology across polyQ disorders, as well as the similar repeat length 
dependence in aggregate formation and pathogenesis, these aggregates (or a structure related to 
them) have been proposed to be the toxic species in polyQ disease. 
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Neuronal nuclear aggregates of the polyQ containing protein have been identified in each 
of the polyQ diseases [41, 53, 66]. These nuclear aggregates have been found to be ubiquitin 
positive, confirming that they are misfolded protein (ubiquitinylation is a post-translational 
modification that signals degradation of misfolded proteins [67]). As a common feature of all 
polyQ disorders, these nuclear inclusions were hypothesized to cause toxicity through nuclear 
dysfunction [62, 68]. This hypothesis was further supported by cell studies which introduced 
chemically synthesized polyQ peptide aggregates into the nuclei of neuronal cell cultures, 
demonstrating that the presence of polyQ aggregates in the nucleus leads to toxicity, while 
introduction of aggregates to the cytoplasm of these cells had a minimal impact on cell viability 
[69]. In conflict with this hypothesis, nuclear inclusions containing misfolded polyQ are present 
in healthy neurons, and regions of high neuronal loss have been found to lack them, suggesting 
that these inclusions may not, in fact, be the direct cause of toxicity [43].  
A study of the formation of cytoplasmic inclusion bodies in Huntington’s disease 
demonstrates that an increase in the amount of diffuse intracellular huntingtin correlates with cell 
death, while formation of inclusion bodies is actually protective, decreasing both toxicity and 
huntingtin levels elsewhere in the cell [70]. These large inclusions of unfolded protein within 
cells have typically been referred to as aggregates, and were believed to be the only sites of 
aggregates within cells. Recent work has found these inclusions are not the only type of 
aggregates that can be found in cells, however, as fibrillar aggregates have been observed within 
the cytoplasm outside of inclusion bodies [71] These aggregates are relatively small, ~100 nm in 
diameter and 1-2 μm long, and are very similar to fibrils prepared by in vitro experiments. 
Cytoplasmic aggregates, contained both within and outside of inclusion bodies, present an 
alternative to the hypothesis that toxicity is caused by nuclear inclusions. It is also possible that 
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cytoplasmic oligomers (observed in [71]) contribute to toxicity in a manner similar to that 
proposed in other amyloidoses, in which small oligomers are believed to be the toxic species [29, 
30].  
Yet another proposed mechanism for polyQ toxicity, the toxic monomer hypothesis, 
suggests the polyQ monomer undergoes a toxic conformational transition that is more favorable 
at increased repeat lengths. This hypothesis is discussed in more detail in Section 1.3.2.2. 
The work described here is based on the premise that aggregated structures of polyQ 
(rather than monomer) are important to disease manifestation. By characterizing the fundamental 
mechanisms of aggregation in vitro, we can gain a better understanding of the pathogenesis of 
polyQ disease. 
1.3 AGGREGATION OF POLYGLUTAMINE CONTAINING PEPTIDES 
1.3.1 In Vitro PolyQ Aggregation 
Simple polyQ peptides have characteristic aggregation kinetics. When the aggregation pathway 
is presented as an aggregate concentration vs. reaction time graph, it typically assumes a 
sigmoidal shape [72]. This curve is representative of three dominating phases within the 
aggregation pathway. During the initial lag phase, no detectable aggregates are forming as 
monomeric polyQ begins to nucleate and elongate amyloid fibrils. Unlike a number of other 
amyloid forming peptides, polyQ appears to be resistant to secondary nucleation, so this phase is 
dominated by the formation of a primary nucleus and initiation of elongation [73]. Because 
secondary nucleation is not a contributing factor, the shape and duration of this lag phase can be 
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used to determine the size and stability of the amyloid nucleus, using a simple, straightforward 
mathematical model, as described below (1.3.5.1) [74]. Confirmation that this lag phase can be 
attributed to nucleation can be achieved through introduction of fibril seeds. By introducing 
preformed nuclei and maintaining a low monomer concentration, elongation of the introduced 
seed is energetically favored over spontaneous nucleation.  
The second phase of polyQ aggregation is characterized by a steep increase in the 
sigmoidal curve. This phase is dominated by polyQ fibril elongation through monomer addition 
to the nucleated fibril. Aggregate concentration continues to increase until the third phase of the 
pathway, at which point monomer and aggregates slowly tend toward a dynamic equilibrium. 
The monomer component of reactions that have reached completion is not eliminated, but 
equilibrates as defined by the critical concentration, Cr (as described above, 1.1.2). When this 
equilibrium is reached, an aggregation reaction is described as having run to completion. These 
characteristic aggregation kinetics allow for the application of mathematical models that define 
this polymerization mechanism [22, 75]. One of these models is described in greater detail below 
(Section 1.3.5.1). 
1.3.2 Structural Steps of PolyQ Fibril Formation 
1.3.2.1 The PolyQ Monomer Ensemble 
In an effort to learn more about intrinsically disordered proteins and the conformations they 
assume [76], numerous studies of monomeric polyQ peptides have been conducted. Monomeric 
polyQ peptides, both longer and shorter than the repeat length threshold in disease, are 
disordered in solution [64, 77, 78] and adopt compact coil structures in water [79-82]. This result 
is surprising because Gln residues are not hydrophobic, and would be expected to maintain 
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interactions with solvent in a random coil. FCS data indicates that a compact coil is favored; that 
is, aqueous solutions are poor solvents for polyQ peptides. The compact coil structure is assumed 
because chain-chain interactions are favored over side chain-solvent interactions. More 
specifically, side chain-backbone hydrogen bonds have been demonstrated to be the main 
stabilizing force in the polyQ compact coil [83]. Insolubility in water is a likely driving force 
behind the aggregation of polyQ fibrils, which form amyloid as a means of maximizing both 
peptide-peptide and peptide-solvent interactions. 
According to the thermodynamic model of nucleation described in 1.3.5.1, any nucleus 
structure that forms from these compact coil monomers must form through an energetically 
unfavorable reaction. This reaction must either consist of protein folding steps which occur as 
the compact coil monomer assumes the structure of a monomeric nucleus, or some combination 
of folding and association that transpire as a multimeric nucleus is formed. When considered in 
terms of the energetics of folding [84], the compact coil monomer is stabilized by both the 
conformational entropy of its disordered state, as well as enthalpic contributions from hydrogen 
bonds and other stabilizing interactions that might occur within this conformation. In order to 
form the nucleus, it is necessary to first disrupt this compact coil structure—the existing side 
chain-backbone and water-backbone hydrogen bonds must be broken before the β-sheet 
stabilizing backbone-backbone hydrogen bonds essential to amyloid structure can be formed. 
Entropic contributions resulting from introducing order to a previously disordered structure must 
also be overcome. The nucleus likely has fewer stabilizing interactions than the compact coil, 
since it is unclear whether the side chains can be fully hydrogen bonded intramolecularly within 
the nucleus. Further, in the case of a multimeric nucleus, association of multiple molecules must 
occur, which require overcoming of a diffusional entropy barrier. 
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Through analysis of aggregation kinetics (monitored by sedimentation assay, 2.2.1) and 
application of a thermodynamic model for nucleated polymerization (1.3.5.1) to a series of 
peptides with repeat lengths ranging from Q23-Q27, it was confirmed that polyQ peptides of 
repeat length 26 or greater aggregate via a monomeric nucleus. Below this threshold, however, 
peptides aggregate via multimeric nuclei, with Q23 assuming a tetrameric nucleus [18, 74, 85]. 
Understanding the underpinnings of this mysterious shift in nucleus size in the Q23 to Q26 region 
is one of the main goals of the research described in this thesis. 
A β-hairpin has been proposed as a likely choice for the structure of the monomeric 
nucleus for polyQ aggregation [18, 19]. The β-hairpin structure is also consistent with structural 
data (described below, 1.3.2.4) that indicates it could be the building block of polyQ amyloid. 
This hypothesis has been justified by experiments in which β-turn encouraging mutations are 
introduced into short repeat length peptides. Insertion of D-Pro-Gly and Trp-zip motifs to the 
center and termini (respectively) of Q23 analogs result in a decrease in nucleus size (n*) from 4 to 
1 (1.3.2.5) [19]. These small modifications to the polyQ sequence lower the energy barrier that 
must be overcome by short repeat length peptides in order to assume a β-sheet rich, monomeric 
nucleus structure similar to the one formed by unbroken polyQ peptides with physiological 
repeat lengths. These data suggest that simple polyQ peptides are nucleated by and form fibrillar 
assemblies consisting of β-hairpins.  
Even though these mutations enhance polyQ peptides’ ability to nucleate through a β-
hairpin structure and are expected to make the same energetic contributions to polyQ as they do 
in other peptides, they have no directly measurable effect on the structure of monomeric polyQ 
in solution, which exists in compact coil [19]. The lack of measurable impact on structure is due 
to the fact that the hairpin structure is so disfavored in the equilibrium between monomer and 
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nucleus that even a multi-fold improvement of nucleus stability results in an structural 
enhancement that cannot be directly observed but is only inferred in the nucleation kinetics.  
1.3.2.2  The Toxic Monomer Hypothesis 
The toxic monomer hypothesis originated from studies in which polyQ specific antibodies bound 
to longer repeat length polyQ expansions more efficiently than shorter Gln repeats. The proposed 
explanation was that the higher repeat length peptides assumed a unique conformation that the 
shorter peptides did not [86]. 1C2, a polyQ conformational antibody, was found to preferentially 
bind to longer repeat lengths of polyQ, leading to the suggestions that it is the expansion of the 
Gln stretch in these polyQ peptides that results in adoption of a toxic conformation [87]. Later, 
the 3B5H10 antibody in particular appeared to preferentially bind an anti-parallel β-sheet 
conformation of polyQ that seemed to be formed by longer repeat length polyQ peptides [88]. 
Because long polyQ repeat expansions tend to more efficiently form β-sheet rich structure (i.e. 
fibrils), and because 3B5H10 appears to be a better predictor of neurodegeneration (compared to 
other polyQ binding antibodies) it was argued that this purported β-rich conformer is a toxic 
monomer species of polyQ [52, 87-89]. This claim was further rationalized by data interpreted to 
indicate that β-hairpin structures introduced to cells are toxic [90]. 
Disputing this hypothesis, the improved binding of some of similar antibodies to long 
polyQ peptides was proposed to be the result of a “linear lattice” model, in which longer polyQ 
binds to antibodies more efficiently because it has more ligand-binding sites than shorter, non-
pathological polyQ sequences [91]. Additionally, new structural studies indicating that both long 
and short polyQ have similar structures, and that the 3B5H10 epitope is actually a short, linear, 
extended conformation of polyQ  further discredit claims of the existence of a compact, toxic 
monomer [78, 92].  
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β-sheet rich structures are a common feature of all polyQ fibrils (which are, by definition, 
β-sheet rich), and are simply formed more rapidly by longer repeat lengths, which have an 
increased tendency toward aggregation [74, 93]. PolyQ monomers of a variety of lengths, on the 
other hand, have been demonstrated to favor compacted coil, not β-sheet structures in aqueous 
solution (described in detail above, 1.3.2.1) [79]. Finally, no direct evidence of a link between 
any such conformer and toxicity has been presented that does not unequivocally rule out the 
formation of aggregates that then act as toxic species [88, 90]. 
1.3.2.3 PolyQ Oligomers and Non-fibrillar aggregates 
Simulations of simple polyQ aggregation have suggested the formation of oligomeric species, 
within which the nucleus of amyloid formation has been proposed to form [94]. Similarly, in 
vitro experiments have resulted in the appearance of transient oligomers [95], but these structures 
have not been demonstrated via kinetic analyses to contribute to amyloid formation. It has been 
suggested that the appearance of these oligomers is due to differences in sample preparation [18], 
as polyQ oligomeric species have been observed under certain aggregation conditions [64, 65].  
Along with changes in aggregation conditions, alterations to the simple polyQ peptide 
sequence have been found to result in oligomer formation. Addition of histidine residues to a 
simple polyQ peptide results in fibril formation via an oligomeric intermediate in acidic 
conditions but not at neutral pH [73]. While the presence of these oligomers is associated with 
slowed aggregation kinetics, they have not been demonstrated to contribute to the nucleation 
mechanism. Htt-exon 1 model peptides are capable of aggregating via an oligomeric 
intermediate mediated by HttNT (described in detail 1.3.3.2) [96]. There is no experimental 
evidence at this time for polyQ mediated interactions leading to kinetically important oligomer 
formation.  
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1.3.2.4 PolyQ Amyloid 
PolyQ peptides generally form β-sheet rich, amyloid-like structures when aggregated. X-ray 
fiber diffraction studies of fibrils formed by polyQ peptides with repeat lengths ranging from 9-
45 demonstrate that, regardless of repeat length, all polyQ fibrils are comprised of slab-like β-
sheet structures [97]. One interpretation of x-ray diffraction data proposes that β-strands of 
polyQ peptide aggregate into anti-parallel β-sheet with interchain hydrogen bonds (between both 
backbone and side chain amides) in the direction of fibril growth [20]. Gln side chains 
interdigitate across the β-sheet in a direction perpendicular to the fibril axis (Figure 1-4 B). This 
structural model supports the idea of β-hairpins as building blocks of polyQ fibrils (Figure 1-4 
A). In addition, CD, FTIR and solid-state NMR (ssNMR) data of both simple polyQ and htt-exon 
1 model peptide fibrils confirm β-sheet rich structures with rigid, solvent protected cores [15, 96, 
98]. 
 
Figure 1-4. Structure of PolyQ β-strands. 
A β-hairpin model for polyQ (A), this structure is believed to act as both nucleus and building block within amyloid 
fibrils. Gln side chains interdigitate to enhance stable elongation as they form β-sheet (B) From CH and PVW, data 
from [20]. 
To test whether a multistrand β-sheet was a good structural model for polyQ amyloid 
formation, multiple L-Pro-Gly or D-Pro-Gly motifs were introduced to long polyQ peptides [99]. 
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L-Pro-Gly insertions were introduced at Gln segment lengths of 7, 8, 9, or 10, to create the 
following sequence K2QN(PGQN)3K2 (referred to as PGQ peptides). The Q9 and Q10 containing 
peptides aggregated quickly, at rates comparable to an uninterrupted Q45 peptide, supportive of 
the hypothesis that polyQ peptides form a four stranded, antiparallel β-sheet. The shorter 
peptides aggregated considerably more slowly, most likely because the uninterrupted Gln chain 
length is not capable of efficiently forming β-sheet. Since the L-Pro-Gly based turns are believed 
to require incorporation of a Gln on either side (to result in a four residue turn, -QPGQ-), the 
shortest amino acid stretch that supports efficient β-sheet formation must contain seven Glns 
exclusive of those involved in turns (such as in the PGQ9 peptide). Substitution of D-Pro-Gly for 
L-Pro-Gly in the Q9 context further accelerates aggregation, most likely due to an improved 
ability to form two residue turns, in particular β-hairpins [100]. When the extended β-sheet in the 
PGQ peptides is broken by Pro insertions, aggregation kinetics are significantly diminished and 
sometimes eliminated, confirming that formation of stable extended β-sheet is essential to fibril 
formation. 
 This four-strand model was further tested with an htt-exon 1 model protein expressed in 
mammalian cells [101]. As in the previously described experiments, PGQ constructs were used 
to induce an alternating β-strand, turn structure in the polyQ region of htt-exon 1 proteins. The 
htt-exon 1 containing PGQ9 repeats aggregated significantly and was toxic to cells, while the 
same protein with Pro residues interrupting the Gln stretches was stably expressed but resulted 
neither in detectable aggregates nor toxicity. These results suggest that the ability to form a β-
sheet rich, amyloid-like aggregated structure is critical to induce toxicity of polyQ sequences. 
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1.3.2.5 β-turn inducing mutations 
Experimental methods to test the nature and roles of β-hairpin structures in polyQ aggregates 
necessitate the use of β-hairpin encouraging mutations. Some of these, such as L-Pro-Gly and D-
Pro-Gly motifs, have been discussed, but there are a number of other β-hairpin encouraging 
mutations, some of which have been incorporated into the sequences listed in Table 1-3   [100, 
102-106]. 
Table 1-3. Hairpin encouraging mutations affect n*. 
Peptides 
K2Q23K2 K2Q10PGQ11K2 D2Q23K2 K2Q10pGQ11K2 K2CQ22CK2h 
AcWQ11pG
Q11WTGK2 
n* 
3.9 1.4 1.6 0.7 0.8 0.9 
 
Peptides 
AcWQ16WTGK2 AcWQ18WTGK2 AcWQ21WTGK2 AcWQ22WTGK2 
n* 
4.6 4.4 3.1 2.7 
Modified from [19]. 
 Experiments using disulfide bonds, Trp-zip motifs and attractively charged residues at the 
termini of Q23 analog proteins all enhanced aggregation and decreased nucleus size from a 
tetramer (Figure 1-5, Table 1-3) [19]. Disulfide bonds, addition of D-Pro-Gly residues to the 
center of the sequence, and the combination of a Trp-zip with D-Pro-Gly all resulted in 
aggregation through a monomeric nucleus. The D-Pro-Gly sequence, however, is the best choice 
for any potential studies of the roles other flanking sequences may have on aggregation of 
monomeric polyQ, as it is the only mutation to stabilize a monomeric nucleus with no change in 
the terminal sequences of the peptide. 
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Figure 1-5. Aggregation kinetics of hairpin encouraging peptides [19]. 
1.3.2.6 Summary 
Taken as a whole, these structural data of polyQ peptides build a basic picture of the transitions a 
molecule must undergo as it evolves from disordered monomer to a highly ordered and rigid 
amyloid fibril. As we gain more information regarding the thermodynamics and kinetics of fibril 
assembly and initiation, this structural information will be important to the development of a 
clearly defined mechanism of aggregation. By combining the existing knowledge of polyQ 
aggregation properties and structure with new data describing the biophysical contributions of a 
peptide’s primary structure to its aggregation, this work clarifies the impact various structural 
features have on polyQ aggregation. 
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1.3.3 Flanking Sequences in PolyQ Aggregation 
1.3.3.1 Solubilizing charges are required to study simple polyQ aggregation 
In vitro studies of polyQ disease proteins make use of either chemically synthesized or 
recombinantly expressed peptide models. Due to their insolubility in water, simple polyQ 
peptides require addition of solubilizing charges to their termini [77, 107, 108]. Addition of 
positively charged Lys residues as a solubility aid is common practice when working with poorly 
soluble, hydrophobic peptides [109]. Thus, nearly all in vitro studies of simple polyQ peptides 
have been conducted with a pair of Lys residues on both N- and C-termini.  
When pure polyQ sequences proved insoluble in the first in vitro studies of polyQ 
peptides, a 15-residue Gln sequence was solubilized with four charged residues, two Asp on the 
N-terminal end, and two Lys on the C-terminus [108]. Once the polyQ peptide was successfully 
solubilized, it was possible to generate aggregates and study their structure. This work found that 
solubilized polyQ peptides aggregate into highly stable, β-sheet rich structures, likely consisting 
of β-hairpins with strong hydrogen bonding.  
Subsequent studies of a similar peptide (K2Q15K2) revealed that while soluble in aqueous 
solution, it still formed aggregates that could be pelleted out by ultracentrifugation [77]. Addition 
of longer Ala and Lys containing sequences to the N-and C-termini led to complete 
solubilization of both long and short (17 and 9 Glns, respectively) polyQ peptides. When 
completely solubilized, these polyQ with short expansions were found by CD to be soluble 
random coil. 
Other studies indicate that, at low concentrations, simple Q22 (with no flanking residues) 
is soluble, and that it forms β-sheet rich structures [110], rather than random coil as previously 
proposed [77]. The conclusion was that the ability of a given polyQ peptide sequence to form 
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large, β-sheet rich structures is what determines its propensity to aggregate, and that interruptions 
to the polyQ sequence impede the ability of polyQ to form β-sheet might inhibit disease 
progression. 
The disagreement between these two studies ([110] and [77]) regarding whether simple 
polyQ monomer exists as random coil or β-sheet in aqueous solution raised a number of 
fundamental questions regarding the approach to in vitro studies of polyQ. In [111], Altschuler 
argued the importance of ensuring the starting material is monomeric, and claims there is 
insufficient data to justify the assertion that polyQ monomer forms β-sheet [110]. Sharma 
counters that Altschuler’s use of large, non-physiological flanking sequences to solubilize polyQ 
(in [77]) may have played a role in the observation of random coil as the structure of short polyQ 
peptides, and suggests a series of more physiologically relevant flanking sequences [112]. Both 
arguments raise valid points: the first is that to make accurate arguments about the polyQ 
monomer structure and the aggregation pathway, it is critical to first guarantee a fully 
disaggregated monomer as the starting material. The second is that it is important to consider 
how the sequence context of polyQ might influence the peptide’s properties before using their 
behavior to draw more generalized conclusions about simple polyQ expansions. 
In an effort to ensure that all starting material for polyQ peptide studies is monomeric and 
entirely disaggregated, our lab developed a disaggregation protocol [107], described in detail in 
section 2.1.2. This disaggregation protocol was combined with tests of a series of flanking amino 
acids to determine the optimal choice for solubilizing relatively long polyQ peptides (~30 Glns) 
[65]. The use of flanking charges has a notable and dramatic effect on the solubility of polyQ 
peptides, but no discernible effect on the final morphology of the resulting aggregates. Lys pairs 
were chosen as the optimal solubilizing flanking residues, as they appeared to have the greatest 
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solubilizing effect, resulting in decreased aggregation propensity of Q15 when compared to 
D2Q15K2 and DKQ15DK. Increasing solubility of the polyQ sequence with these charged residues 
allowed for more detailed studies of longer, more physiologically relevant repeat lengths than 
had been previously conducted. 
1.3.3.2 Disease relevant flanking sequences can impact aggregation mechanism 
Peptide models of huntingtin (htt) exon 1 have demonstrated that both the N-terminal 17 amino 
acids (HttNT) and the C-terminal poly-Pro region play important roles in modulating aggregation. 
When their impacts on polyQ aggregation are considered individually these sequences have 
interesting effects. Addition of a poly-Pro segment 6-10 repeats long to the C-terminus of polyQ 
causes a marked decrease in the rate of aggregation and stability of the resulting fibrils [51]. Use 
of only 3 Pro residues or attachment of a poly-Pro (of length 10) to the N-terminus of the peptide 
did not have any observable effects on polyQ aggregation. These C-terminal poly-Pro 
modulations had no effect on the calculated nucleus size and were found to hinder aggregation of 
Aβ in a similar manner. It is believed that the decreases in aggregation rate and fibril stability are 
due to a change in the conformational ensemble so it contains fewer aggregation competent 
monomer conformations with the Pro extension than without it. These effects are of particular 
interest because of the presence of both N- and C-terminal Pro-rich regions in a number of polyQ 
proteins (as mentioned in 1.2.1). 
Incorporation of the HttNT sequence to either the N- or C-terminus of polyQ results in a 
significant acceleration in aggregation rate [96]. When both HttNT and a poly-Pro region are 
added to polyQ (to the N- and C-termini respectively), the enhancement effects of the HttNT 
sequence dominate—this htt exon 1 model peptide aggregates faster than the same length simple 
polyQ. In spite of the apparent dominance of the HttNT sequence, HttNT -QN peptides still 
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demonstrate a repeat length dependence similar to that of simple polyQ. Work to determine 
whether this repeat length dependent aggregation of exon 1 model peptides is related to 
modulating effects of HttNT, the repeat length dependence of simple polyQ (discussed below in 
1.3.4), or both is ongoing. 
The full htt exon 1 model peptide, containing both HttNT and poly-Pro regions, is capable 
of aggregating through a two-step pathway [96]. In the first step, modulated by HttNT, the N-
termini associate to form oligomers. Then, since the local polyQ concentration is enriched, the 
expanded polyQ chains exhibit a greatly enhanced ability undergo conformational changes to 
nucleate amyloid, and β-sheet rich, amyloid fibril formation is initiated. The end products of this 
reaction are amyloid fibrils in equilibrium with exon 1 monomers: any remaining non-amyloid 
oligomers resulting from the first step of this mechanism are expected to dissociate back into 
monomer. Thus, addition of a flanking sequence as short as 17 amino acids can result in a 
dramatic change to the aggregation mechanism.  
Ataxin 3 is also capable of forming fibrils via a mechanism with two distinct steps [113]. 
The first, governed by the N-terminal Josephin domain, occurs regardless of Gln repeat length, 
and results in the formation of SDS sensitive amyloid. The second part of the pathway is 
dominated by polyQ interactions and results in formation of a more stable, SDS resistant fibril. 
In both of these systems, polyQ mediated aggregation acts as the key step in a series leading to 
the formation of amyloid such as that observed in vivo (while the non-polyQ mediated steps are 
important, they do not result in the formation of aggregates comparable to those found in disease 
states).  
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The presence of a polyQ mediated aggregation mechanism even within the context of 
disease relevant peptides is significant, and indicates that furthering our understanding of the 
simple polyQ aggregation pathway is essential to an understanding of these disorders. 
1.3.4 PolyQ Demonstrates Repeat Length Dependent Aggregation 
Repeat length dependent aggregation of polyQ in vitro correlates well with the repeat length 
dependence of pathogenicity [74]. Studies of recombinant exon 1 confirmed the repeat length 
dependent aggregation of polyQ both in vitro and in vivo for repeat lengths ranging from 20 to 
51 [63, 114] (with repeat lengths less than 32 forming no detectable aggregates) and presented 
data that suggested in vitro aggregation is consistent with a nucleation dependent mechanism. 
For repeat lengths greater than 32, aggregation of exon 1 was dependent on both protein 
concentration 2 and time—a specific concentration of monomer was required to initiate 
aggregation, and aggregation was always preceded by a lag-phase, the length of which decreased 
with increasing repeat length. Furthermore, addition of a preformed seed eliminated the lag 
phase, all features consistent with a nucleated growth mechanism. 
Synthetic simple polyQ peptides also demonstrate repeat length dependent aggregation 
[64, 74]. PolyQ peptides with the sequence K2QNK2, where N = 5, 15, 28, 36, 42, 44, and 47 
were synthesized, disaggregated, and their aggregation kinetics were monitored via ThT binding 
or sedimentation assay (methods described in 2.2.1 and 2.2.2). The Q5 and Q15 peptides 
underwent little detectable aggregation during the course of these experiments (though Q15 
                                                 
2 Amount of aggregate was determined by filtration to isolate aggregates followed by binding with an anti-
AG51 antibody (specific to exon 1 aggregates) via dot blot and subsequent quantification. 
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aggregation has been detected with extremely long incubation periods). The larger peptides 
demonstrated features of nucleated growth, with lag phases that decreased with increases in Gln 
count, and monomeric nuclei. Fibril stability as measured by Cr (critical concentration) also 
varied with repeat length: short peptides had high Cr values (Cr for Q15 was ~30 μM), while the 
Cr was notably decreased for the longest repeat lengths (Cr for Q44 was ~70 nM). These results 
suggest that increasing repeat length leads to increasingly favorable polymerization.  
PolyQ peptides of repeat length 26 or greater have been demonstrated to aggregate via a 
monomeric nucleus, while shorter peptides have been found to aggregate through multimeric 
nuclei, indicating a clear relationship between repeat length and nucleus size of simple polyQ 
peptides (1.3.2.1) [18]. This switch in nucleus structure might explain the repeat length 
dependence of polyQ in the 20’s, but leaves the basis for repeat length dependence in longer 
peptides unclear. 
Repeat length also appears to play a role in fibril structure: vibrational spectroscopy 
studies of polyQ peptides ranging in repeat length concluded that while all polyQ fibrils have 
similar secondary structures (as observed by vibrational circular diocroism), there are detectable 
morphological differences in the structures formed by polyQ with repeat lengths greater than 35 
as compared to those with 30 or fewer Gln residues [115]. Hydrogen exchange data indicates that 
longer repeat length polyQ fibrils exhibit a less protected core than shorter fibrils, in spite of 
increased fibril stability, suggesting differences in the core β-sheet structure that makes up these 
fibrils. The proposed threshold for these structural differences again lies between Q30 and Q35, 
similar to the repeat length threshold commonly observed in disease. 
The in vitro effects of repeat length on both aggregation and structure may have 
implications on the pathological repeat length threshold observed in disease. Could it be that 
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polyQ diseases only manifest when repeat length surpasses 30 because of the challenges 
involved in initiating nucleation when a monomeric nucleus is not favored? Aggregate structure 
may also play a pathogenic role, as it also appears to have a repeat length dependence as detected 
through fibril stability and spectroscopic measurements. This leaves us questioning whether 
repeat length dependence of pathogenicity is a result of the influences of Gln count on the 
aggregate structure, or on the rate and degree of aggregation of polyQ peptides. 
1.3.5 Mathematical Models for PolyQ Aggregation 
1.3.5.1 A Nucleated Polymerization Model of Aggregation 
In spite of extensive study, there is still much that remains to be learned about polyQ aggregation 
and amyloid formation. In particular, the initiation of fibril formation is still largely a mystery. 
Developing an understanding of this critical nucleation step is essential to our understanding of 
amyloid fibrils.  
According to a thermodynamic nucleated polymerization model for aggregation 
developed by Eaton and Ferrone [22], the thermodynamic nucleus exists as a maximum energy 
transition state that the system must pass through in order for spontaneous aggregation to occur 
(Figure 1-6). Because, by definition, the nucleus is the highest energy structure on the 
aggregation pathway, it is also the least stable and least populated structure along the path to 
amyloid formation, further challenging any studies of its nature. Its crucial position as a rate 
limiting step in the aggregation pathway makes studies of the nucleation phase of amyloid 
formation essential to our understanding of amyloid fibrils themselves. Furthermore, a thorough 
knowledge of amyloid nucleation may allow for treatment of disease by preventing initiation of 
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Figure 1-6. Thermodynamic model of polyQ aggregation. 
 A simple free energy diagram of polyQ aggregation (A). The nucleus exists as an unstable, high energy state, 
resulting in its role as a rate limiting step in the folding pathway. Two free energies describe this pathway, the free 
energy of nucleation (ΔGn*) and the free energy of elongation (ΔGelong). Only the molecules which form the amyloid 
nucleus must surpass the ΔGn*, after the nucleus is formed, the energy barrier is lowered for elongating molecules.  
An illustration of the steps in the polyQ fibrillization mechanism (B). Disordered monomer folds into a nucleus, 
which elongates by monomer addition into a fibril. In order to generate his simple mechanistic model, it was 
assumed by Ferrone that elongation of the nucleus and fibril proceed identically, and that k+=k+n*. 
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fibril formation. Development of an experimental model of the nucleation mechanism may make 
it possible to finally design and test therapeutics that target amyloid fibril nuclei. 
The thermodynamic model of homogeneous nucleation developed by Eaton and Ferrone 
has been successfully applied to polyQ aggregation [22, 74, 116, 117]. According to our 
application of this model, the polyQ amyloid nucleus exists in an equilibrium state with the 
compact coil monomer, with the compact coil structure heavily favored (Figure 1-6B). For 
simple polyQ peptides, elongation of the nucleus occurs through monomer addition, a much 
more energetically favorable process than nucleus formation. 
Early phase aggregation kinetics are analyzed to determine nucleus size (n*), as well as a 
complex parameter (log(½k+2Kn*)) that relates the nucleation equilibrium constant (Kn*) and rate 
constant for fibril elongation (k+). This complex parameter is indicative of a peptide’s ability to 
undergo spontaneous aggregation, and can be used to compare the impacts changes to the polyQ 
sequence have on aggregation efficiency. 
Further amalysis helps us untangle the log(½k+2Kn*) parameter. The pseudo-first order 
rate constant (k*) is measured by fitting seeded elongation reaction kinetics. When an 
appropriate amount of seed is used, a constant number of elongation sites are maintained, so 
elongation is solely dependent on monomer concentration. Biotinyl-polyQ titration experiments 
make it possible to determine of the amount of growing ends in a seed sample. Concentration of 
growing ends and k* are used to determine the second order elongation rate constant, k+ which 
corresponds to the rate at which monomer adds to the growing fibril. Determination of k+ allows 
for isolation of Kn* from the complex parameter mentioned above [85]. The free energy of 
nucleation (ΔGn*) can be calculated from this nucleation equilibrium constant. These approaches 
are discussed further in Methods (2.1.5, 2.2.4, 2.2.5, 2.2.6) and Chapter 3.0. 
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In Ferrone’s mathematical treatment of the Eaton and Ferrone model, in order to simplify 
equations to make possible an approximate solution, k+n*, the rate at which monomer adds to the 
nucleus is assumed to be identical to k+, the rate at which monomer adds to fibrils. This equality 
is justified by the argument that on-rates are predominantly defined by long-range interactions, 
such as diffusion, with electrostatics possibly having some effect. These long-range forces are 
not expected to change much as the nucleus grows into a fibril, and so it is possible to justify 
k+n*≡k+.  
In addition, our lab has found that by monitoring reactions as they run to completion and 
conducting dissociation reactions it is possible to determine the critical concentration (Cr) and 
from it the free energy of elongation (ΔGelong) for a given peptide (as described in 1.1.2). 
These thermodynamic and kinetic values characterize both the nucleus and final amyloid 
product, and allow us to define key steps in fibril formation. The ability to extract 
thermodynamic quantities specific to each peptide sequence allows for the determination of the 
importance of various structural features in amyloid assembly [19]. The mathematical methods 
used in these calculations are explained in detail in the Methods chapter (2.2.6) and based on 
those described and derived in [22]. Our use of this model is further justified by its excellent fit 
to our polyQ data, as illustrated in later chapters of this work (see Figure 4-7, Figure A-1-
Figure A-9, Figure A-11-Figure A-15). We also never see the products of heterogeneous 
aggregation mechanisms, either by EM or other methods such as DLS [18], confirming our 
choice of a model of homogeneous nucleated aggregation mechanism to fit simple polyQ 
aggregation. 
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1.3.5.2 Alternate Models of Aggregation 
The above model is not the only mathematical treatment of aggregation and nucleation. The 
Weissman group developed a mathematical model which fits the aggregation kinetics of Sup35, 
a yeast prion protein [118]. Secondary nucleation plays a significant role in the aggregation 
mechanism of this protein. By modifying the Ferrone model described above, it was possible to 
generate a model consistent with amyloid nucleation through a nucleus of n*≤ 3. Elongation then 
occurred by subsequent monomer addition, followed by secondary nucleation through 
fragmentation [119]. Though oligomers were observed during the aggregation of Sup35 [34], 
elongation appears to be dominated by monomer addition, not association and rearrangement of 
oligomeric species, at least at the relatively low concentration of the Weissman experiments. 
Fortunately, simple polyQ aggregation does not undergo secondary nucleation, so an alternative 
approach such as this is not necessary for our studies. 
 An alternative to the model of Chen et al. (described in 1.3.5.1) [74] has been proposed 
based on a heterogeneous model of polyQ aggregation [120]. This model assumes the presence 
of on-pathway oligomeric intermediates that undergo conformational conversion into a nucleus 
structure, which is then elongated by monomer or oligomer addition. As discussed previously 
(1.3.2.3), however, there is no experimental evidence of on-pathway oligomers in the simple 
polyQ aggregation mechanism, and application of the previously described homogeneous model 
of polyQ aggregation mechanism has been confirmed to be an equally good fit in estimating 
values such as nucleus stability [121]. 
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1.3.6 Fundamental Questions Being Addressed 
1.3.6.1 Flanking sequences in polyQ peptide aggregation 
The use of flanking charges in studies of polyQ peptides has become commonplace (1.3.3.1). 
Simple polyQ peptides are insoluble and spontaneously aggregate upon introduction to aqueous 
solution at pH 7, but addition of 4 Lys residues (2 at each terminus) solubilizes the monomer and 
allows for the study of aggregation kinetics [65]. Concerns have been raised regarding the 
influence of introducing a strong positive charge to the termini of polyQ peptides [122], and the 
role the electrostatics of these amino acids play in the polyQ aggregation mechanism is unclear. 
Small additions to the polyQ peptide sequence can have major impacts on peptide aggregation 
properties [19, 99]. The difference in physiological repeat length between different CAG-repeat 
diseases, and recent studies of htt-exon 1 model peptides suggest that the sequences flanking the 
polyQ region are important in modulating the mechanism of polyQ aggregation [51, 96, 123, 
124]. Consideration of these facts leads to a series of important questions: how many charges are 
necessary to solubilize polyQ? Is fibril morphology affected by the magnitude of the net charge? 
Under what circumstances do flanking sequences have a significant impact on aggregation 
mechanism or ability? How might the impact of flanking sequences vary with a change in repeat 
length? Do flanking sequences affect one portion of the aggregation mechanism more 
significantly than others? 
1.3.6.2 Repeat length dependence 
The repeat dependence of polyQ disease manifestation has been previously discussed (1.2.2). 
Similar repeat length roles have been identified in in vitro studies of polyQ, in which the size of 
the polyQ expansion plays a role in both elongation kinetics and nucleation of amyloid [18, 74]. 
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In spite of the clear importance of repeat length both in the disease state and experimental 
studies, little has been done to discern the biophysical implications of changes in Gln content. 
Will a more detailed study of repeat length thermodynamics confirm previous reports of 
correlations between fibril stability and repeat length? What trend exists between stability and 
repeat length (i.e. will there be discontinuities)? What role does repeat length play in nucleation 
efficiency? Is there an energetic explanation for why short repeat lengths (such as Q23) are not 
observed to aggregate via a monomeric nucleus? Is there an energetic explanation for why 
aggregation rates continue to increase as repeat lengths increase, even among the family of 
repeat lengths which aggregate via a monomeric nucleus? 
1.4 PRELIMINARY STUDIES 
1.4.1 Peptide Design 
1.4.1.1 Optimization of peptide length 
To measure the quantitative and qualitative effects of charged flanking sequences, it is essential 
to first develop the appropriate polyQ core context. This work utilizes two polyQ frameworks for 
the studies of flanking charges. The guiding factor in the selection of these core sequences was 
the understanding that peptides exhibiting monomeric aggregation nuclei are simplest to 
interpret, since nucleation in this case is reduced to a protein folding problem, rather than a 
combination of folding and association [51]. 
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Figure 1-7. Positive and negative effects on hairpin closure due to terminal charge interactions. 
Use of repulsive terminal charges on termini can be expected to lead to ‘fraying’ of the termini (left), and act as a 
destabilizing force in the closure of a β-hairpin structure. If there are more residues than the absolute minimum 
necessary to stabilize a closed hairpin (top), this effect can result in minimization of the interactions between the 
termini. Use of attractive charges on termini (right) supports hairpin closure. 
To measure quantitative changes and maximize charge interactions between the N- and 
C-termini during both fibril elongation and nucleation, a polyQ sequence containing a D-Pro-Gly 
β-hairpin favoring mutation was selected. This peptide was chosen to ensure monomeric 
nucleation in a short polyQ, while minimizing any mechanism changes that might be introduced 
by variations in flanking sequence charge. To ensure that the influence of terminal charges on 
aggregation was accurately measured, it was necessary to use a peptide that minimized 
separation of the termini and flexibility in the hairpin structure. Optimization of the number of 
residues that contributed to stabilizing interactions within the hairpin by decreasing the overall 
Gln repeat length was expected to accomplish this goal.  When decreasing Gln repeat length, it is 
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also important to consider peptide aggregation time: as repeat length is decreased, aggregation 
time increases significantly, eventually (at low enough repeat lengths) making it difficult to 
obtain quality, interpretable data. To determine the shortest polyQ β-hairpin peptide with an n* 
of 1 (or monomeric nucleus) that can be feasibly studied, two peptides were considered: 
K2Q10PDGQ10K2 and K2Q9PDGQ9K2 (Figure 1-8). 
Both peptides were found to aggregate via monomeric nuclei, though aggregation of the 
Q9 based peptide was significantly slower than aggregation of the Q10 peptide. While Q8 or even 
Q7 based peptides might maintain a monomeric nucleus (based on data in [99], only seven Gln 
residues capable of interacting are necessary to form stable β-sheet), their aggregation kinetics 
would be prohibitively slow when initiated at feasible (based on amounts of peptide that can be 
acquired) concentrations. 
Of particular note is the significant influence the D-Pro-Gly insertion has on otherwise 
short Gln repeat lengths. Normally, peptides Q25 and shorter have multimeric nuclei, but in the 
case of K2Q9PDGQ9K2, a Q20 analog peptide is still monomeric because of the influence of the β-
hairpin encouraging mutation. Because both the Q10 and Q9 peptides have monomeric nuclei, the 
slopes of the fit lines in the log-log plot are parallel (Figure 1-8 B). The significant displacement 
in the data between the two peptides corresponds to the notable differences in kinetics as 
illustrated in (Figure 1-8 A), and suggests that they are not due to a change in nucleus size, but 
instead an effect of peptide length on elongation efficiency and nucleus stability (as indicated by 
the y-intercept of the log-log plot). The magnitude of this efficiency difference, as measured in 
the difference in the y-intercepts of the log-log plots, plays an important role in validating the 
approach to understanding repeat length effects described in Chapter 5.0. Otherwise, this 
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experiment resulted in our choice of the Q9 peptide as one of the model systems for the study of 
charge effects (Chapter 4.0). 
 
Figure 1-8. Aggregation of K2Q10PDGQ10K2 and K2Q9PDGQ9K2. 
The kinetics of K2Q10PDGQ10K2 (■) and K2Q9PDGQ9K2 (○) at concentrations of 125.6 μM and 128.9 μM, 
respectively (A). In spite of the similarities in reaction concentration, the Q10 peptide aggregation rate is 
significantly faster than that of the Q9 peptide. The log-log plots of these two peptides reveals nearly identical 
slopes, and therefore similar n* values (B). The Q10 peptide has an n* of 0.98, and the Q9 peptide n*=0.81. Both of 
these values are consistent with those typically observed for monomeric nuclei. 
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2.0  EXPERIMENTAL METHODS 
2.1 PEPTIDE PREPARATION AND REACTION PROTOCOLS 
2.1.1 Peptide Synthesis and Purification 
All peptides used in these studies were synthesized by solid-phase synthesis and obtained crude 
from the Keck Biotechnology Center (http://medicine.yale.edu/keck/ssps/index.aspx) in 
synthesis scales of 25-100 μM. All crude peptides were stored at -20°C for the short term and -
80°C for long term prior to purification. 
Crude peptides were purified using reverse phase chromatography on an Agilent Zorbax 
C3 column connected to a Biorad Biologic Dual Flow system. Peptides were dissolved in 100% 
formic acid (Sigma) for 2-3 minutes, until completely dissolved. The peptide-formic acid 
mixture was then diluted to 20% formic acid with deionized water prior to injection onto the 
reverse phase column. It is important to be sure that the peptide is injected shortly after having 
been dissolved in formic acid to prevent formylation of the sample. Any formylation that does 
occur can be isolated via the purification step and would be detected by MS if any remained with 
the purified peptide sample. The buffers used for purification were water (Fisher Scientific, 
HPLC grade) with 0.05% trifluoroacetic acid (TFA) (Sigma) as buffer A, and acetonitrile (Fisher 
Scientific, HPLC grade), also with 0.05% TFA (Sigma) as buffer B. To ensure a clean column 
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prior to peptide injections, “blank runs” of 20% formic acid injections were performed prior to 
each peptide purification run. All purification methods maintained a solvent flow rate of 4 
mL/minute with a buffer B gradient optimized to the peptide being purified. Eluted fractions 
were collected using a Biorad fraction collector in volumes of 0.3-0.8 mL per tube. Purity of the 
desired peptide in each fraction across the major peak (based on absorbance at 218 nm) was 
confirmed by electrospray ionization mass spectrometry. Peptides with a purity of 95% or higher 
were pooled, lyophilized for at least 4 hours (until completely desiccated), and stored at -20°C 
until disaggregated in preparation for aggregation reactions. 
2.1.2 Peptide Disaggregation and Reaction Preparation 
To ensure all aggregation reactions were initiated free of any aggregate material that might affect 
results, all peptides were disaggregated as a standard part of reaction preparation [107, 125, 126]. 
Pure, lyophilized peptides were brought to room temperature and dissolved in a 1:1 mixture of 
TFA and hexafluoroisopropanol (HFIP) (Acros Organics) to a peptide concentration of ~100 
μg/mL in a glass scintillation vial. The peptide-solvent mixture was left to sit overnight 
(approximately 16 hours) before evaporation under a stream of nitrogen using the Organomation 
N-EVAP evaporator (Fisher Scientific). The resulting film was put under vacuum for 
approximately 1 hour to remove any remaining organic solvent that may have been left behind 
after nitrogen evaporation. The dried film was then dissolved in acidified water (brought to pH 
3.0 with TFA) and centrifuged at 100,000 rpm (416,640 x g) in a bench top ultracentrifuge 
(Optima TLX, Beckman) for 2-3 hours. Approximately 60-70% of the solution from the top of 
the supernatant was used as the peptide stock for reaction preparation. 
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 Peptide stock concentration was determined (see below) and subsequently reduced to 
desired reaction starting values at 1x PBS using 10x PBS (Fisher Scientific) and deionized water. 
Reaction mixes were filtered with a 20 nm membrane filter (Anotop 10, Whatman) to maximize 
removal of aggregates. The filtrate was then used as the reaction mixture. 
 Reactions were conducted at 37°C unless otherwise indicated. Some fibril samples were 
prepared at low temperatures as described in [127]. In these cases, the prepared reaction mixture was 
flash frozen and stored at -80°C before transfer to -20°C for incubation. 
2.1.3 Peptide mass confirmation by mass spectrometry 
The mass of peptides were confirmed with electrospray ionization mass spectrometry on an 
Agilent electrospray 1100 mass spectrometer. Peptides were injected by auto-sampler onto an 
Agilent C8 reverse phase column prior to their injection into the MS. Peptide masses were then 
determined using the in-built Agilent ChemStation software. 
2.1.4 Peptide concentration determination 
Peptide concentrations were determined using an Agilent analytical RP-HPLC system. Peptides 
were injected by the auto-sampler onto an Agilent C8 column and eluted using an acetonitrile 
buffer prepared identically to the purification buffer B. The elution profile was monitored by 
absorbance at the A215nm detector channel and the area of the elution peak was determined using 
Agilent ChemStation software. The area under the curve was converted to peptide concentration 
using a standard curve that related amount of peptide to HPLC area [128]. This curve is 
determined by using the extinction coefficient at 215 nm (calculated using the method described 
 43 
in [129]) to calculate peptide concentration for 4-5 samples using an absorbance 
spectrophotometer. These calibrated samples were then injected into RP-HPLC and the area 
under the curve was plotted against the corresponding concentration determined by the 
absorbance value to form the standard curve. Generally, each chemically different peptide 
requires a different standard curve. 
2.1.5 Dissociation reactions 
Dissociation reactions were initiated with end stage fibril samples. An aliquot was removed from 
the completed reaction mixture, and diluted in 1x PBS. The goal was to bring the remaining 
monomer concentration sufficiently below the apparent Cr value (based on the end-stage plateau 
monomer concentration from the forward reaction) to allow observation of an increase in 
monomer concentration as aggregates dissociated when the mixture returns to equilibrium. At 
the same time, the total amount of peptide in the diluted reaction must be substantially greater 
than the Cr, sufficient to ensure that some fibrils will still be present at equilibrium.  For 
example, if a forward reaction had a starting concentration of 100 μM, and appears to equilibrate 
at 1.5 μM of monomer, a 10-fold dilution will bring the monomer concentration to 0.15 μM (well 
below the expected Cr), while maintaining a total peptide concentration of 10 μM in the reaction 
mixture, ensuring a clear store of aggregates at equilibrium. 
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2.2 ANALYSIS OF AGGREGATION KINETICS 
2.2.1 Sedimentation Assay 
The sedimentation assay protocol is a long-established method in our lab for monomer 
concentration determination during aggregation reactions [65, 125]. In this method, aliquots of 
reaction mixture are removed, and centrifuged at 14,000 rpm on a bench top centrifuge 
(Eppendorf). The top portion of the supernatant (no more than half of the centrifuged volume) 
was then carefully removed and mixed in a 1:1 ratio with formic acid to prevent further 
aggregation. The monomer concentration of the reaction (equivalent to the concentration of the 
monomer remaining in the supernatant) was then determined by injection into a reverse phase 
HPLC as described in section 2.1.4, above. 
2.2.2 Thioflavin T Binding 
The ability to bind dyes such as ThT and alter its fluorescence is an identifying characteristic of 
amyloid fibrils [3]. Though the nature of this interaction is still unclear, this property is 
commonly utilized to confirm peptide aggregation into amyloid, and to follow aggregation 
kinetics. While ThT is an excellent test for overall aggregation kinetics and final amyloid 
formation of polyQ peptides, this method is limited in its ability to report on initial polyQ 
aggregation kinetics, in particular in a manner sufficiently quantitative to be used in subsequent 
thermodynamic calculations, and is therefore used sparingly in these studies. 
Experiments with ThT binding to polyQ peptides were conducted by mixing an aliquot 
from aggregation reactions (260 μL) with ThT in excess (12 μL of 2.5 mM stock). Fluorescence 
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was measured on a FluoroMax-4 fluorometer from HORIBA Scientific, with an excitation 
wavelength of 445 nm, a detection wavelength of 489 nm, and slit widths of 2 nm. For all sample 
measurements, a blank reading of ThT at an identical concentration in 1x PBS free of peptide 
was subtracted from sample readings. 
ThT readings were most frequently reported as a % aggregate by equating the final ThT 
reading (a plateau) to the final % aggregate as measured by HPLC via the sedimentation assay. 
2.2.3 Dynamic light scattering 
Dynamic light scattering (DLS) was used in these studies primarily to confirm the size of 
aggregate seeds used for seeding elongation and growing end reactions [18]. For these 
measurements, 70 μL of filtered PBS was added to a 384-well microplate, and a blank reading 
was taken using a DynaPro plate reader (Wyatt Technology) to confirm the absence of air 
bubbles and other small particles that might affect a reading of peptide sample. An aliquot of 10 
μL of the desired peptide sample was then gently mixed into this same microplate well and a 
measurement was taken immediately to ensure accurate reading of the desired aggregate sample. 
All measurements were taken at 37°C and for 5 seconds/scan. Typically 10 scans were averaged 
to determine aggregate size. In all cases, the scans were confirmed to converge to a particular 
value to ensure accurate reporting of sample size free of contaminants such as micro-bubbles or 
dust. 
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2.2.4 Seeded elongation reactions 
In all cases, seeded elongation reactions were conducted with end stage aggregates of the desired 
seed [125]. The weight of peptide incorporated into aggregates was confirmed by subtracting the 
final monomer concentration from the initial reaction concentration (both as determined by 
sedimentation assay), this concentration value corresponds to the amount of peptide incorporated 
into aggregates and were easily be converted to weight per unit volume. Unless specifically 
noted, seeds for elongation reactions were sonicated on ice using a Fisher Scientific probe 
sonicator (Sonic Dismembrator, Model 500) at 40% power for a total of 5 minutes, with 30 
seconds of sonication alternated with 30 seconds rest. When necessary, seed size was confirmed 
immediately following sonication by DLS (as described in section 2.2.3). 
An aliquot corresponding to a particular amount of aggregate of this sonicated sample 
was then added to a freshly prepared and filtered reaction. Reaction kinetics were then followed 
as usual for both this seeded and an identically prepared unseeded reaction. 
The initial 20% of the seeded elongation was used to determine the pseudo- first order 
elongation rate constant, k*. These kinetics data were graphed as the ln [peptide] versus time, 
and the slope of the linear fit to the data corresponds to k*. k* can be considered a pseudo-first 
order elongation rate constant in seeded reactions where second order nucleation is not a factor 
because, while the aggregate mass increases, the number of elongation sites does not, thus the 
elongation rate of this reaction appears to be dependent only on monomer concentration. The 
actual elongation rate constant for the seeded fibril formation reaction, k+, is second order, being 
dependent both on amount of monomer and the number of elongation sites. For all peptides, two 
separate seeding reactions (each with seeds prepared from unique samples) were conducted and 
averaged to determine these values. 
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2.2.5 Growing ends reaction 
It is important to determine the number of growing ends present in a reaction in order to 
calculate the concentration of aggregates and hence the second order elongation rate constant 
(k+) from k*. This second order elongation rate universally applies to all amyloid reactions of a 
given peptide, and is much more useful toward a complete understanding of peptide aggregation 
and thermodynamics than the pseudo-first order elongation rate, which has a fibril concentration 
term embedded within it. 
In order to facilitate calculation of k+, growing ends titration experiments must be 
conducted simultaneously with seeded elongation reactions, so that the same aggregate/seed 
preparation can be used for both the seeded elongation reaction and the growing ends experiment 
[85, 125]. For growing ends, 200 ng of aggregates are added to a series of reactions containing 
monomeric biotin-PEG-K2Q30K2 at concentrations ranging from 0 to 10 μM in a volume of 500 
μL. The seeds are allowed to incubate with the biotinylated-Q30 for 30 minutes at 25°C before 
being centrifuged for an hour at 14,000 rpm and 4°C in a bench top centrifuge (Eppendorf). The 
supernatant was removed gently, so as not to disturb the pellet, which was then washed in 100 
μL PBS and centrifuged again at 14,000 rpm for an hour to remove any remaining monomeric 
biotinyl-Q30. This washing step was repeated once more. In all cases, when the supernatant was 
removed 10% of the volume was left to ensure an undisturbed pellet. 
The pellets were then resuspended with 100 μL of europium bound streptavidin solution 
(Perkin Elmer) in a 1:1000 dilution  and incubated in the dark for 1 hour at room temperature. 
The mixtures were again centrifuged and washed twice as previously. The remaining labeled 
pellets were then mixed with 100 μL of enhancer solution (Perkin Elmer) to release europium 
and the mixtures were then added to a 96 well plate and fluorescence counts were read on a 
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PerkinElmer/EG&G Wallac Victor2 microtiter plate reader, which is specially designed to be 
compatible with the DELFIA/time‐resolved fluorescence assays used here. When suitably 
complexed, europium fluorescence can be used to measure concentrations as low as 10-13 M 
[130]. When measuring concentrations expected to be on the order of fM, such a sensitive assay 
is not only helpful, but necessary. 
Background signal was determined from the preparation of aggregates incubated with 0 
μM biotinyl-Q30 as a control. This signal was subtracted from the counts of the other growing 
ends reaction to determine normalized values. These normalized fluorescence counts were 
converted to femtomoles of europium using a standard curve determined in-lab from a stock 
europium solution. Femtomoles europium were then converted to femtomoles biotinyl-Q30 using 
the manufacturer’s quoted number of europium atoms per streptavidin molecule and an assumed 
1:1 binding ratio of streptavidin to biotin molecule. This value was converted to the 
concentration of growing ends (femtomoles/μg aggregate) based on the use of 200 ng of 
aggregate per growing ends reaction.  
When plotted against the concentration of biotinyl-Q30 used in each reaction preparation, 
the number of growing ends is expected to reach a plateau value. This indicates that all growing 
ends have been saturated, or bound and labeled with biotinyl-Q30 and Eu-streptavidin, and that 
this value is the true concentration of growing ends for a given aggregate sample. The validity of 
the growing ends titration and they underlying basis for how it works are addressed 
experimentally in Chapter 3.0  
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2.2.6 Aggregation and nucleation kinetics 
The Ferrone model [22, 74, 117] discussed in section 1.3.5.1 relates reaction kinetics to 
nucleation as follows:  
C(t) = ½ Kn* k+2[C0]n*+2 t2 . 
The variables C(t) and C0 refer to the monomer concentration over time and the starting 
monomer concentration, respectively, Kn* refers to the nucleation equilibrium constant, n* is the 
nucleus size, and, as mentioned previously, k+ is the second order elongation rate constant, as 
described previously. Using measurements of reaction kinetics, which provide monomer 
concentration with respect to time, we are able to extract the term ½ Kn* k+2[C0]n*+2 as the slope 
from the linear fit to the plot of C(t) versus t2. Graphing the log of this rate versus the log of C0 
allows us to determine values for n* (the slope of this graph is n*+2) and ½ Kn*k+2 (the y-
intercept). 
In order to determine Kn* and k+ individually, we must determine the concentration of 
growing ends of the fibrils and the pseudo-first order rate constant, as described above in section 
2.2.5. By definition, the pseudo-first order rate constant (k*) is related to the rate constant of a 
second order reaction (k+) according to the following equation:  
Rate=k+[A][B]=k*[A]. 
This relation is true when the concentration of B remains constant during the course of the 
reaction. When an aggregation reaction is seeded with a small concentration of pre-formed 
fibrils, the reaction proceeds according to first order elongation kinetics and k* can be 
determined as the slope of the line fit to a log(C0) versus time plot. The concentration of growing 
ends in a given reaction, [B], is determined as described above. The second order rate constant 
(k+) can then be determined using a simplification of the above equation: 
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k+[B]=k*. 
Using this value of k+, it is now simple to determine the Kn* of the peptide in question based on 
the y-intercept of the log-log plot described previously. 
 While these rates and the nucleus size are essential to our understanding of the nucleation 
and elongation of amyloid fibrils, it is the change in free energies of nucleation and elongation 
(ΔΔGn*, ΔΔGelong) that truly allow us to compare the relative impacts of any mutations or 
variation in these peptides. By definition,  
ΔG=-RT ln Keq, 
and therefore  
ΔΔG=-RT ln (Keq1/Keq2). 
In the above paragraph, we explain how Kn* is derived: this value is used as the equilibrium 
constant to determine ΔGn* and ΔΔGn*. 
 The concentration of growing ends in a reaction does not change as the fibrils elongate or 
dissociate near the equilibrium position. At this point, the reaction is in a state of dynamic 
equilibrium defined by an equilibrium constant that is the ratio of the elongation rate to the 
dissociation rate. This term is the binding constant of monomers to fibrils, Ka, which can be 
simplified from [fibril ends]/[monomer][fibril ends] to simply [monomer]-1 [37]. At equilibrium, 
this corresponds to the reciprocal Cr. We can then use the Cr as the Keq to determine the ΔGelong 
and ΔΔGelong, and relate stabilities of different fibrils. 
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3.0  METHOD DEVELOPMENT: UNDERSTANDING THE GROWING ENDS 
TITRATION EXPERIMENT 
3.1 OVERVIEW 
When studying amyloid growth mechanisms, it is important to understand the rates and 
equilibria that govern them. For example, the rate at which disordered monomer adds to a 
growing fibril, the second order elongation rate constant (k+), can be used to identify a number of 
characteristic features of a particular amyloid sample. This value defines the ability of a 
particular fibril to seed growth of a range of peptides, and can be used to compare cross-seeding 
efficiencies of fibrils for a particular monomer [131]. This term is also an essential component of 
thermodynamic calculations regarding amyloid nucleus stability [22, 132], and is necessary to 
isolate the value of the nucleation equilibrium constant, which is particularly difficult to measure 
directly.  
Fibril elongation reactions can easily be fit to pseudo-first order kinetics, but the resulting 
rate constant, k*, is specific to the particular seed preparation and concentrations used as a 
template for elongation, and cannot be generalized to indicate any universal characteristics of 
fibril elongation for that peptide. Determination of the value of k+, in contrast, is much more 
informative, as it describes the dependence of rate on both monomer concentration and the 
average number of growth/elongation sites per unit weight of aggregate ([growing ends]) in a 
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given reaction preparation. While monomer concentration is a fairly straightforward 
measurement, [growing ends] in a given reaction is difficult to isolate. One approach to 
determine [growing ends] is to use an electron micrograph of a fibril sample to guesstimate the 
number of available elongation sites in a given fibril sample [85, 133]. This particular method 
involves a number of assumptions, such as the idea that each filament terminus is capable of 
elongating, and that the EM grid is representative of the sample in solution. This approach is 
clearly less than optimal for use in rigorous calculations that require accurate determination of 
[growing ends], such as the calculation of k+ and subsequent determination of Kn*. 
 
Figure 3-1. Growing ends assay. 
Fibril seeds (blue) are incubated with biotinyl-polyQ, which elongates the fibril. The biotin is then labeled with Eu-
streptavidin, and Eu fluorescence is measured after incubation with enhancer solution (which frees the Eu molecules 
from the streptavidin and allows for detection of Eu fluorescence). Not to scale, the streptavidin tetramer is actually 
much larger than a single polyQ monomer. 
A more quantitative experimental approach to measuring [growing ends] has been 
developed which incorporates labeled monomer onto the ends of growing fibrils via a titration 
assay. The labeled monomer is capable of binding fluorescent molecules, and the resulting 
fluorescence counts correspond directly to [growing ends] (Method described in 2.2.5) [85, 125]. 
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This assay works through the addition of biotinyl-polyQ (biotin-PEG-K2Q30K2) to existing 
fibrils, followed by subsequent labeling with europium complexed streptavidin and detection of 
fluorescence signal (Figure 3-1). The efficacy of this method was confirmed by comparing the 
measured values of [growing ends] to those approximated by the EM method described above 
[85]. 
As initially described [85], an important part of the method was the addition of unlabeled 
K2Q30K2 monomer to reactions after the biotinyl-polyQ incubation, in order to induce subsequent 
rounds of elongation and thereby suppress or prevent dissociation of the labeled molecule and 
loss of signal. In support of this requirement, when the unlabeled monomer incubation step was 
skipped, the signal corresponding to binding of the label was lost, suggesting that added biotinyl-
polyQ molecules were only weakly and transiently bound to the fibril ends. However, 
subsequent experience with the assay led to the realization that the addition of unlabeled 
monomer is actually not required and does not change the signal (MJ, personal correspondence).  
While the reason for this discrepancy is not clear, it is now routine in the lab to conduct these 
titrations without an unlabeled monomer “chase”, and excellent dose and time dependent binding 
is observed [18, 96, 125, 126]. 
While this method appeared to be a reliable approach to determine [growing ends], the 
means by which only one biotinyl-polyQ molecule seemed to add to each growing end were a 
mystery. Our knowledge of elongation rates indicates that polyQ monomers add to fibrils at rates 
on the order of 104 M-1s-1, which corresponds to the addition of 1 molecule every 10 seconds in a 
10 μM reaction. The measured addition of only one biotinyl-polyQ to each fibril growing end 
(with an incubation time of 30 minutes) regardless of whether efforts were made in controlling 
the reaction conditions to only encourage addition of one biotinyl-polyQ, was surprising, and led 
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to the hypothesis that the rate of biotinyl-polyQ elongation might be drastically slowed compared 
to that of simple polyQ. One proposed explanation for this apparent change in rate was based on 
the “dock and lock” model for fibril elongation—biotinyl-polyQ was capable of undergoing the 
“dock” phase as efficiently as simple polyQ, but the conformational rearrangement required 
during the “lock” phase of the mechanism was slowed, delaying presentation of a new elongation 
site to solution, and decreasing the effective elongation rate of biotinyl-polyQ to fibrils. It is also 
possible that once bound (“docked and locked”) the biotinyl-polyQ somehow inhibits addition of 
other monomers. There is currently no experimental evidence for or against either of these 
arguments, leaving us to wonder why this method appears to function so well. 
The experiments described in this chapter were conducted in an effort to learn more about 
this growing ends titration assay, in the hopes that we might be able to arrive at a conclusive 
mechanism by which it acts as well as to confirm its functionality, which was so surprising when 
it was first developed. 
3.2 RESULTS 
3.2.1 Biotinyl PolyQ Elongation of PolyQ Fibrils 
In order for biotinyl-polyQ to allow us to accurately measure [growing ends], it must bind and 
label functional fibril elongation sites in a manner consistent with continuing elongation. If the 
biotinyl-polyQ were adding to seeds in some unproductive way in the growing ends titration, 
then one would expect that it would not be capable of multiple rounds of seeded elongation. 
Seeding reactions were therefore conducted to confirm that biotin-PEG-K2Q30K2 is incorporated 
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into fibrils and elongates seeded material in a manner similar to unlabeled polyQ. Figure 3-2 
illustrates the aggregation reactions of K2Q31K2 and biotin-PEG-K2Q30K2 both in the presence 
and absence of Q31 seeds. Both peptides proved capable of spontaneous aggregation and 
demonstrated enhanced aggregation kinetics when incubated with Q31 seeds.  
 
Figure 3-2. Biotinyl polyQ seeding reactions. 
The aggregation kinetics of K2Q31K2 and biotin-PEG-K2Q30K2 both with and without seed. Concentrations ranged 
from 22-28 μM, and seeding reactions contained approximately 10% seed (end stage Q31 fibrils with 2.5 μM peptide 
incorporated into the fibrils). Seeding enhances aggregation for both Q31 and biotinyl-polyQ, and both peptides 
undergo spontaneous aggregation. 
The seeded simple Q31 peptide reached t1/2 (the time at which 50% of monomer is 
incorporated into aggregates) nearly twice as quickly as biotinyl-Q30, even though the same 
amount of the same seed was used and the starting monomer concentrations were similar. 
Biotinyl-Q30 also demonstrates slower unseeded (spontaneous) aggregation kinetics when 
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compared to simple Q31. Though it aggregates more slowly than simple Q31, Biotinyl-Q30 does 
not demonstrate the characteristic lag phase in its spontaneous aggregation kinetics (this lag 
phase is described in 1.3.1). This could be due to an alteration in the Biotinyl-Q30 aggregation 
mechanism—perhaps the biotins associate to encourage formation of oligomers that are 
pelletable, resulting in this early drop in monomer concentration. If they behave in a manner 
similar to exon 1 oligomers (described in 1.3.3.2), they could serve to aid amyloid nucleation by 
creating a local high concentration of polyQ molecules, then dissociate as fibrils form, leaving 
only monomer and fibril remaining in the end stage reaction. In spite of the slight differences in 
kinetics, these data confirm that biotinyl-polyQ is capable of spontaneous aggregation and 
incorporating itself into existing fibrils, suggesting that there is no impediment to the addition of 
multiple biotinyl-polyQ molecules to the elongation site of a fibril, as previously hypothesized. 
To verify that the enhanced aggregation kinetics biotinyl-polyQ seeded reactions were 
due to elongation of fibrils rather than random association of labeled peptide with seeds, EM was 
used to observe the morphology of these fibrils (Figure 3-3). EM microgrids indicate that 
biotinyl-polyQ forms amyloid fibrils, both with and without seed present, rather than the 
disordered aggregates that might be observed if the peptide were incorporated into seeds more 
randomly. Interestingly, when fibrils elongated with biotinyl-polyQ are fixed to an EM grid and 
labeled with gold nanobeads coupled to streptavidin, the beads tend to localize preferentially to 
the termini of fibrils, even when the fibrils are predominantly made up of biotinyl-polyQ. 
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Figure 3-3. EM micrographs of biotinyl-polyQ fibrils. 
Biotinyl-polyQ is incorporated into fibrils when seeded with K2Q31K2 (A). The morphology is identical for unseeded 
biotinyl-polyQ fibrils. When labeled with streptavidin-nanogold, the nanogold primarily localizes to the termini of 
fibrils, even when they contain more than 80% biotinyl-polyQ (B). To confirm that this nanogold interaction is due 
to the streptavidin attached to the nanogold binding with biotin incorporated into fibrils, the streptavidin-nanogold 
was bound with free biotin before fibril labeling. No binding is observed for these nanogold particles (C). 
 These kinetics and EM data indicate that biotinyl-polyQ is capable of adding more than 
one molecule to the growing end of fibrils. This is surprising because the data used to develop 
this assay were interpreted to suggest that only one biotinyl-polyQ added per growing end [85]. 
This result introduces a series of important questions: if there is incorporation of more than one 
labeled molecule onto the fibril termini, why is it that the number of bound biotinyl-polyQs 
plateaus after a short incubation time, and why does this value correspond so well to the 
estimated number of growing ends in a sample? The nano-gold labeled EM samples suggest a 
possible new mechanism: only the biotin molecules on the termini of the fibrils remain 
accessible.  
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3.2.2 Time dependent elongation with biotinyl-polyQ 
Time dependent fluorescence studies of biotin-Q30 incorporation into fibril seeds similar to those 
conducted during original development of this method [85] were repeated, this time on longer 
time scales (hours as compared to minutes). While the fluorescence counts in these studies did 
increase at a rate similar to the observed rate of aggregation (as measured by sedimentation 
assay), they are not consistent with the amount (in moles) of biotinyl-polyQ that have been 
incorporated into fibrils (Figure 3-4). In fact, the amount of incorporated biotin as detected by 
fluorescent labeling is roughly 5 orders of magnitude lower than the amount indicated by 
sedimentation assay! 
The inefficient labeling with Eu-streptavidin implicit in Figure 3-4 C, D is consistent 
with the streptavidin-nanogold labeled EM results, in which fibrils appear to selectively bind 
nanogold at the termini. Considered together, these EM and time-course fluorescence data 
suggest that biotinyl-polyQ incorporated in the interior of the fibril sequester the biotin molecule 
preventing binding with streptavidin in solution. That is, biotinyl-polyQ molecules that have 
bound the growing end of the fibril maintain a biotin-available state until a conformational 
change or addition of the next monomer sequesters it, preventing binding of streptavidin bound 
nanogold or Eu (see mechanism in Figure 3-9).  
Fibril formation and elongation are reversible folding and association reactions, in which there is 
constant ‘recycling’ of molecules in the system as those at the termini interchange with those in 
solution [134]. Previously, unlabeled monomer was introduced to the reaction subsequent to the 
labeling reaction to prevent dissociation of the labeled polyQ via this molecular recycling [85]. 
However, if multiple labeled molecules are incorporated into the fibrils but only the ‘last on’ is 
counted, this incubation with unlabeled monomer step is unnecessary, as use of a high enough 
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concentration of biotinyl-polyQ to add multiple molecules during the labeling portion of the 
assay plays a similar role—one accessible biotin molecule is always maintained for each 
growing end, even if those near the termini are cycling with monomers in 
 
Figure 3-4. Time dependence of biotinyl-polyQ incorporation. 
The elongation kinetics of 5 μM biotin-PEG-K2Q31K2 with 5% K2Q25K2 -20°C fibril seed (monofilaments) as 
observed by fluorescence (A, C) and  a corresponding (scaled up) reaction followed by sedimentation assay (50 μM 
start concentration, with 5% seed) (B, D). Both approaches demonstrate similar kinetics, but the plateau level of the 
fluorescence reading does not correspond to the amount of biotin that has been incorporated into fibrils (C vs. D)—
when 89% of biotinyl-polyQ are incorporated according to sedimentation assay kinetics, the Eu signal maximum has 
less than doubled and is consistent with available biotin equivalent to only 0.003% of the biotinyl-polyQ.  
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solution. This incubation with unlabeled monomer step has been confirmed to be unnecessary 
within our lab (MJ, personal correspondence), a conclusion is further corroborated by the 
fluorescence data shown in this chapter, which shows significant Eu signal even without the 
addition of unlabeled monomer. 
In addition, if we use the data illustrated in Figure 3-4 to approximate the number of 
elongating biotinyl-polyQ molecules that are incorporated into each growing end, we find that 
there are nearly 35 thousand biotin molecules adding to each growing end (assuming equivalent 
elongation preference for each end). Thus, even if the terminal-most thousand biotinyl-polyQ 
dissociate at some point during the work up of this assay, there are still thousands more 
incorporated into the fibril capable of accepting a streptavidin bound label. 
3.2.3 Growing ends titration accurately reports available growing ends 
Further confirmation of method functionality is necessary to be certain it accurately reports the 
number of growing ends. If the method functions as proposed, an increase in signal should 
correspond to a similar increase in number of available growing ends. By using a seeded 
elongation coupled with the growing ends titration assay on seed material known to vary in the 
number of available elongation sites, it should be possible to confirm method functionality. 
There are a number of approaches that can be used to generate variable numbers of elongation 
sites in otherwise identical fibril seed samples, but the two most straightforward approaches are 
by varying seed mass used in the growing end titration, and by maintaining the same seed mass 
but fragmenting the fibrils to result in variable numbers of growing ends. 
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3.2.3.1 A first attempt: varying the seed mass 
The simplest approach to introducing a variable number of elongation sites to the biotin titration 
assay would seem to be using different amounts (by weight) of seed in the assay. Usually 200 ng 
of seed are used for the titration assay, so experiments were conducted using both more (400 ng) 
and less (100 and 50 ng) of an identical seed preparation, while maintaining all other conditions 
equal. Using this approach, the titration assay reactions with more seed should have higher 
fluorescence counts, corresponding to more growing ends, while those with less seed should 
have lower fluorescence counts, as they have fewer elongation sites. The data for these 
experiments are shown in Figure 3-5. 
 
Figure 3-5. Growing ends titration data from reactions with variable amounts of seed. 
Four masses of seed were used to perform the growing ends assay. All four samples resulted in similar fluorescence 
count values, which, when corrected for the amount of aggregate to generate fmol of growing ends/ μg aggregate, 
leads to a surprising result. Smaller amounts of seed appear to generate more signal per growing end then larger 
amounts. 
 Contrary to expectations, larger amounts of seed appeared to have fewer labeled growing 
ends while the titrations with less seed gave higher fluorescence readings. A possible explanation 
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for this lies in the centrifugation steps used to isolate biotinyl-polyQ bound aggregate seeds. 
Larger amounts of aggregate could result in a greater number of aggregates being buried within 
the pellet prior to the Eu-streptavidin labeling step. These inaccessible aggregates then are not 
completely resuspended during Eu-streptavidin labeling, and are therefore not fully labeled. Thus 
when fluorescence counts are measured, amounts of seed >200 ng appear to have fewer growing 
ends, even though this is not the case and Eu-streptavidin was added in excess of the possible 
number of added sites.  
 Since the use of variable amounts of seeds was not an effective means of confirming that 
this biotinyl-polyQ titration assay functions as predicted, and in fact gave counterintuitive 
results, another approach was necessary, this time designed to maintain the same weight of 
aggregates, but with variable amounts of elongation sites. 
3.2.3.2 Sonication generates samples with variable amounts of elongation sites 
Sonication of amyloid fibrils has been demonstrated to result in an improvement in elongation 
efficiency. This change is proposed to correspond with an increase in elongation competent fibril 
ends that result from fracturing of the fibrils [125]. By applying varying sonication energies and 
times to fibril samples from the same stock preparation, it should be possible to generate a series 
of seed samples with variable amounts of growing ends. When the growing ends titration is 
conducted with these samples, each unique seed sample should yield a number of growing ends 
consistent with the amount of fracturing it has undergone. 
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Figure 3-6. Seeded elongation and growing ends data (14 krpm centrifugation). 
Seeded elongation of Q25 with 6% seed demonstrates sonication of the aggregate used as seed has a very slight 
enhancement on elongation ability when compared to use of a larger, unsonicated seed (~2000 nm). Both seeded 
reactions accelerate significantly more rapidly than an otherwise identical unseeded reaction. The growing ends 
titration assay, however, indicates that the large, unsonicated seeds have approximately 2.5 times the number of 
growing ends as sonicated seeds, an unexpected result. 
For these experiments, fibrils were prepared using the Q25 peptide at -20°C. Under these 
conditions, polyQ forms fibrils that appear to be a single filament by EM, and these more fragile 
fibrils are capable of being fractured by sonication into seeds of sizes as small as 50 nm (when 
measured by DLS) [127, 135]. Samples of 200 ng of aggregate were used as seed for this study, 
consistent with the typical approach for the method (2.2.5). Sonication for 10 sec at a power of 
40% with a probe sonicator (2.2.4) generated 200 nm seeds. When unsonicated, fibrils had an 
average size of ~2000 nm. The growing ends titration assay was followed as described in 
Methods section 2.2.5 using these two seed samples. Contrary to expected results, smaller 
aggregates appeared to have fewer elongation sites, in spite of a slightly enhanced seeding ability 
(Figure 3-6). This result suggests that the 14 krpm centrifugation that is used to pellet labeled 
aggregate may not be generating sufficient force (or may not have been run long enough) to 
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quantitatively pellet the small, 200 nm seeds. Loss of these seeds during any of the many 
centrifugation steps could explain the artificially low number of elongation sites we detect as 
during the growing ends titration experiment. Therefore, a second attempt was made using an 
ultracentrifuge to pellet the aggregate seeds at 100 krpm for all centrifugation steps. The results 
of the growing ends titration (Figure 3-7) are not interpretable and suggest that an alternative to 
the centrifuge must be used to isolate labeled aggregates. 
 
Figure 3-7. Variable seed size growing ends titration (ultracentrifugation). 
When ultracentrifugation is used to pellet aggregates, there is no detectable trend in labeling of sample or number of 
elongation sites. The inconsistency of this data proves the ineffectiveness of this approach to confirm functionality 
of the growing ends titration assay. 
Table 3-1. Sonication impacts on growing ends. 
Seed size (determined by DLS) [growing ends]/μg aggregate  
100 nm * 71 
200 nm 38 
700 nm 13 
~1500 nm (unsonicated) 9 
~2000 nm (unsonicated) * 13 
Experiments were performed on two separate seed preparations with otherwise identical characteristics, starred 
values were performed on one sample, while unmarked values a second.  
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One final attempt was made to generate and study variably sized seeds, the characteristics 
of which are listed in Table 3-1. As an alternative to centrifugation, a filter trap assay was used 
to recover and count labeled aggregates. Biotinyl-polyQ labeled seeds were prepared as usual, 
but before incubation with Eu-streptavidin, they were run through a vacuum filtration apparatus 
with a cellulose acetate filter (Whatman) with a pore size of 200 nm. A series of wash steps were 
run before and after Eu-streptavidin was added to label the bound fibrils. The membrane 
containing the labeled aggregate was then submerged in 100 μL enhancer solution, and sonicated 
for 2 min in a bath sonicator to free the bound Eu. All 100 μL were then removed to a 96 well 
plate, and the fluorescence counts were measured as usual. 
 
Figure 3-8. Seeded elongation and growing ends titration with variably sized seeds (filter trap). 
When labeled fibrils are isolated using a filter trap, [growing ends] increases as seed size is decreased (A). Seeded 
elongation reactions were conducted simultaneously, with 25% (B) or 0.5% (C) seed. In both cases, smaller seeds 
are more efficient at elongation. This improvement in elongation is more evident when more seed is used, as in (B). 
The resulting amounts of growing ends are listed in Table 3-1 and shown in Figure 3-8 
A. These values are consistent with the expected trend based on sonicated seed size, and 
enhancement of aggregation kinetics observed in corresponding seeded elongation reactions 
(Figure 3-8 B and C). The smallest seeds provide the most growing ends for the same mass of 
seeds, while those that have undergone no sonication (and are the largest) have the least. 
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Unfortunately, it is impossible to verify a loss of seeds during the filter trap assay, making a 
quantitative comparison of these values difficult to justify. It is possible that growing ends values 
for the small seeds in particular may be artificially low due to loss of aggregates during this step. 
Since these small seeds still generate the expected higher fluorescence counts when compared to 
large seeds, we believe any sample loss that may occur is fairly modest, and does not impede our 
confirmation of the functionality of this mechanism. 
3.3 DISCUSSION 
The goals of the work described in this chapter were to attempt to confirm functionality and to 
develop a mechanism that could explain how a commonly used lab assay is able to accurately 
report the number of elongation sites in a fibril sample. The series of experiments conducted to 
this end led to mixed results which were often difficult to interpret. 
Experiments indicating increases in the number of elongation sites in a given sample of 
seed correspond to increases in the measured number of growing ends (as observed by 
fluorescence counts) suggest that this assay is capable of at least qualitatively reporting the 
amount of elongation sites in a given sample. These functionality studies also indicate that the 
mass of fibrils studied (200 ng) and the average seed size are important to accurate measurement 
of [growing ends]. If too little or too much aggregate (by mass) is used, there may be effects on 
the efficiency of the labeling step. Likewise, the use of seeds that are very small (<100 nm), 
prevents formation of a dense pellet during centrifugation, and leads to inaccurate results. Use of 
a filter-trap apparatus makes isolation of small aggregates possible, but it is difficult to confirm 
that no sample is lost using this method. 
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The data presented here point to an experimental mechanism in which multiple biotinyl- 
polyQ elongate the fibril seed during the labeling phase. Our ability to match [growing ends] 
counts determined by multiple methods may be because the terminal-most biotinyl-polyQ 
maintains a solvent accessible biotin molecule, while those more internal to the fibril have 
undergone a conformational change during a “locking” phase of elongation, sequestering the 
biotin molecule, so they are no longer accessible to streptavidin in solution. If this proposed 
mechanism is correct, the growing ends titration experiment can be expected to consistently 
report the amount of growing ends in the reaction, so long as spontaneous aggregation of the 
biotinyl-polyQ does not occur. 
 
Figure 3-9. Proposed mechanism for growing ends titration assay. 
Incubation of polyQ seeds with biotinyl-polyQ leads to addition of multiple biotinyl-polyQ molecules. When the 
biotinyl-polyQ first binds/”docks” the biotin remains accessible. Upon “locking” the biotinyl-polyQ undergoes a 
conformational change to sequester the biotin, making it inaccessible within the fibril. Biotinyl-polyQ on the 
growing end that has not undergone conformational change maintains an accessible biotin that binds Eu-streptavidin 
and yields the fluorescence signal. 
 In the original publication describing this method, experiments in which labeled fibrils 
were incubated with simple Q30 in a quenching step still generated signal, indicating that 
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internalized biotinyl-polyQ are capable of binding streptavidin [85]. There are a number of 
differences between that experiment and those presented here, however, that could explain these 
inconsistent results. For one, labeled fibrils were elongated with simple polyQ, not biotinyl-
polyQ. It could be that the internal biotin molecules are only sequestered when biotin groups on 
nearby labeled molecules interact, so elongation with simple polyQ leaves biotin molecules free 
to bind streptavidin.  
It is also possible that the binding ratio of streptavidin to biotin is less than 1:1. A single 
streptavidin molecule is capable of binding multiple biotins, so if multiple biotin groups are close 
enough together (as they might be after a short elongation reaction, such as the one conducted in 
[85]) there might be only one label per growing end, either because streptavidin is bound to 
multiple biotins, or because it is blocking the binding of other streptavidin. In a reaction in which 
biotinyl-polyQ elongates a fibril over a long time frame (such as the experiments shown in 
Figure 3-4), we would expect the portion of the fibril containing biotin molecules to ultimately 
lengthen beyond the reach of a single streptavidin molecule, resulting in an increase in signal as 
new biotins become accessible. While the data shown in Figure 3-4 indicate the number of 
labeled sites does increase beyond 2 hours (the scope of the experiment in [85]), the plateau 
value still corresponds to less than double the amount of peptide being labeled between 2 and 
200 hours, when the sedimentation assay indicates that more than double the amount of biotinyl-
polyQ has been incorporated into aggregates. If this effect were solely due to streptavidin 
molecules binding more than one biotin, 1 streptavidin would have to bind or block 
approximately 106 biotin molecules, which is orders of magnitude beyond the two biotin binding 
sites that actually exist in a streptavidin molecule, and significantly higher than we might expect 
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to see from a blocking effect. Thus, the above proposed mechanism (Figure 3-9) is still the most 
likely explanation for how this biotin titration assay functions. 
 Unfortunately, the experiments performed in this chapter do not provide a satisfactory 
mechanistic basis for this assay. The repeated challenges in acquiring data with straightforward 
interpretations, and inconsistencies between more recently conducted experiments and those 
used in the development of this assay force the question of whether this assay is accurately 
reporting the values it was designed to measure. Data acquired using this approach in Chapters 
4.0 and 5.0  are also confusing. Luckily, it is still possible to determine a number of 
thermodynamic parameters that define the polyQ aggregation mechanism in the absence of this 
assay; it is these parameters that are the main focus of the next two chapters. 
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4.0  TERMINAL CHARGE STUDIES OF POLYQ PEPTIDES 
4.1 OVERVIEW 
As discussed in the Chapter 1.0, the flanking sequences of polyQ expansions play fundamental 
roles in disease progression and aggregation mechanism, both in vivo and in vitro. The use of 
positively charged, Lys residues as solubilizing agents for in vitro studies of simple polyQ 
aggregation has been brought into question due to the electrostatic impact charged termini may 
have on the peptide aggregation mechanism [122]. By adding positive charges to the termini of 
polyQ peptides, it might be argued that stereoelectronic hindrances could be introduced that 
affect a peptide’s ability to assume structures essential to its aggregation, such as the β-hairpin 
nucleus, or the β-strand-turn-strand complex fundamental to the polyQ amyloid structure. 
 In an effort to identify both the qualitative and quantitative roles charged flanking 
sequences have on aggregation mechanism, rates, fibril stability and other fundamental 
thermodynamic terms, we have designed a series of 10 peptides. These peptides consist of a set 
of flanking charges in the context of two polyQ core sequences. The first core sequence, 
containing a central D-Pro-Gly, was selected to gain a quantitative perspective on the rates of 
aggregation with minimal effects on the mechanism (1.4.1.1). A simple polyQ core, consisting of 
26 Gln residues was chosen as a more physiologically relevant option. Since the Gln sequence is 
rarely interrupted in disease states, it is important to consider a simple polyQ model. The repeat 
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length of 26 was chosen in an effort to maximize the amount of polypeptide involved in essential 
structure (i.e. stabilizing β-sheet), assuring maximal interaction of charged terminal residues 
while maintaining an n*=1. Since maintaining a monomeric nucleus is essential for quantitative 
comparisons, a repeat length of at least 26 was required given our prior knowledge of n* 
dependence on repeat length [18]. This simple polyQ peptide serves as a qualitative measure of 
the role of charged flanking residues on the aggregation mechanism, as it is more prone to 
mechanistic change than the D-Pro-Gly containing peptide, which has steric constraints 
encouraging structure formation. 
Table 4-1. Terminal charge peptides and charge characteristics. 
Peptide Symbol Net charge 
Repulsion 
Intramolecular Intermolecular 
K2Q26K2 □ 3.8 2.8 14.44 
KQ26K3 ○ 3.8 3.6 14.44 
Q26K ∇ 0.8 0 0.64 
KQ26D  -0.2 -3.6 0.04 
K2Q9PDGQ9K2 ■ 3.8 2.8 14.44 
KQ9PDGQ9K3 ● 3.8 3.6 14.44 
KQ9PDGQ9K ▲ 1.8 0 3.24 
Q9PDGQ9K ▼ 0.8 0 0.64 
KQ9PDGQ9D  -0.2 -3.6 0.04 
K2Q9PDGQ9D2  -0.2 -8.4 0.04 
Symbols are used in figures throughout this chapter to illustrate properties of these peptides unless otherwise 
indicated. All D-Pro-Gly peptides are indicated by filled symbols, while simple polyQ are indicated by unfilled 
symbols.  
 The peptides investigated in this study are listed in Table 4-1, along with their charge 
properties. The net charge of each molecule was calculated by estimating the approximate charge 
on the peptide at pH 7.3 (as determined using the null model [136], in which an average pKa 
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value determined from 78 proteins is used to determine charge [137]), with the N-terminal α-
amino group (pKa≈8) assigned a charge of +0.8, Lys side chains (pKa=10.4), +1, Asp side chains 
(pKa=3.9),-1, and C-terminal α-carboxyl group (pKa≈3.7), -1. Repulsion was considered to be 
proportional to the force experienced between charges as defined by Coulomb’s law  
(F = A |q1q2|/r2, where F corresponds to force, A is a constant, q1,2 are the two charges in 
question, and r is the distance between them). Therefore, the intramolecular repulsion was 
calculated by multiplying the summed charges on the termini, and intermolecular repulsion was 
calculated by squaring the net charge of the molecule (identical to multiplying the charge on two 
like molecules). 
4.2 RESULTS 
4.2.1 Impact of Terminal Charges on Kinetics and Morphology 
All of the peptides investigated this study proved to be capable of spontaneous amyloid 
formation. A preliminary survey of the aggregation kinetics of each of the 10 peptides (at similar 
concentrations) is illustrated in Figure 4-1. In general, we found that as repulsion between the 
peptide termini is decreased, aggregation rate increases in both model frameworks. These 
changes in aggregation rate are early indications that varying terminal charge does have an 
impact on the kinetics of polyQ aggregation. Further thermodynamic analysis is necessary, 
however, in order to determine the specific role these flanking sequences have on the polyQ 
aggregation mechanism. 
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Figure 4-1. Aggregation kinetics of all terminal charge peptides. 
Changes in terminal charge do have a notable effect on aggregation rate, in spite of similar initial monomer 
concentrations. D-Pro-Gly containing peptides are illustrated in (A) and simple polyQ in (B) at the following start 
concentrations: K2Q9PDGQ9K2 80 μM (■), KQ9PDGQ9K3 61 μM (●), KQ9PDGQ9K 69 μM (▲), Q9PDGQ9K 68 μM 
(▼), KQ9PDGQ9D 55 μM (), K2Q9PDGQ9D2 60 μM (), K2Q26K2 40 μM (□), KQ26K3 34 μM (○), Q26K 40 μM 
(∇), and KQ26D 40 μM (). 
End stage aggregate morphology was also confirmed via EM (Figure 4-2). The 
morphology of most of the fibrils appears to be within the range of what we typically observe for 
simple polyQ peptides, but non-amyloid structures were present in the EM images of a few 
peptides. In these latter cases, the EM micrographs indicated these alternate morphologies were 
co-populating the reaction with amyloid fibrils. This introduction of new morphologies may be a 
primary indication of mixed aggregation mechanisms for some peptides in this series. 
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Figure 4-2. EM images of end stage aggregates. 
Characteristic EM images of all ten peptides: each peptide is capable of adopting the characteristic polyQ fibril 
morphology, but some generate alternative structures (C, D, G, H, L). The peptides imaged and the reaction start 
concentration from which they originated are as follows: (A) K2Q9PDGQ9K2: 181 µM, (B) KQ9PDGQ9K3: 45 µM, 
(C) KQ9PDGQ9K: 150 µM, (D) KQ9PDGQ9K: 12 µM, (E) Q9PDGQ9K: 88 µM, (F) K Q9PDGQ9D: 78 µM, (G) 
K2Q9PDGQ9D2: 112 µM, (H) K2Q9PDGQ9D2: 46 µM, (I) K2Q26K2 43 μM, (J) KQ26K3 63μM, (K) Q26K 108μM, (L) 
KQ26D 20μM 
4.2.2 Fibril Stability 
The role of terminal charge electrostatics on fibril stability can be determined using the Cr 
(critical concentration) of a given peptide. The Cr is determined by measuring the final 
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concentrations of the fibril dissociation and/or association reactions (Figure 4-3, 2.1.5). The free 
energy of fibril elongation is then approximated using the expression: ΔGelong = ̵ RT ln (1/Cr). 
This free energy describes the energy required to add a disordered monomer to the elongating 
fibril—a more positive value indicates a less stable fibril structure, while a more negative value 
corresponds to a more stable fibril. For the fibrils investigated in this study, the ΔGelong values lie 
within a narrow range, between -32 and -36 kJ/mol (Table 4-2). This small difference indicates 
that terminal charges have only subtle effects on fibril stability.  
 
Figure 4-3. Association and dissociation reactions meet at the Cr. 
Association (open triangles) and dissociation (filled) reaction of Q26K. The original reaction start concentration was 
68.2 μM. Both association and dissociation approach a Cr value of 0.66 μM, indicated by the dashed line. 
Even within these subtle changes in free energy, it is possible to identify clear influences 
of flanking charges on fibril stability. For example, a comparison of ΔGelong values with the 
intramolecular repulsion term (Table 4-1) demonstrates that fibril stability increases with the 
attraction between terminal charges (Figure 4-4 A). The most stable fibrils are those with 
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opposite (attractive) terminal charges (,,), while like (repulsive) charges (□, ○,∇, ■, ●, ▲, 
▼) lead to a decrease in stability. The linear correlation of ΔGelong with intramolecular repulsion 
is fairly robust, with the D-Pro-Gly series yielding a slightly steeper slope than the simple Q26 
peptides. These data support the hypothesis that successful and favored closure of a β-hairpin is 
important to fibril stability and the energetics of amyloid formation. 
 
Figure 4-4.  Free energy of elongation vs. repulsion. 
Free energy of elongation, as calculated from the critical concentrations of all peptides studied graphed against the 
intramolecular (A) and intermolecular (B) repulsion of each peptide. 
The fact that intramolecular repulsion (Figure 4-4 A) proves to be more destabilizing to 
fibril structure in the D-Pro-Gly series than the simple polyQ series justifies our selection of two 
distinct core structures for these experiments.  The gentler slope of the fit to the Q26 trend 
indicates that this series experiences relatively little effect in fibril stability as a result of 
variations in terminal charge, most likely due to flexibility in the termini of these peptides which 
allows the terminal segments to pull apart without preventing amyloid formation (Figure 1-7). 
Thus, K2Q26K2 fibrils (□) are only destabilized by a ΔΔGelong of 0.54 kJ/mol compared to KQ26D 
fibrils (), while K2Q9PDGQ9K2 fibrils (■) are destabilized by a ΔΔGelong of 3.67 kJ/mol 
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compared to KQ9PDGQ9D () (Table 4-2).  The increased impact of terminal charges on the 
stability β-hairpin mimetic peptide fibrils is predominantly due to our design criterion that 
minimized chain terminus flexibility in the D-Pro-Gly fibrils. 
Table 4-2. Terminal charge thermodynamic values. 
* Since these peptides did not demonstrate n*=1, further analysis of their thermodynamic properties were not 
conducted, and these values were not acquired or calculated. 
Correlation of ΔGelong with intermolecular repulsion (Figure 4-4 B) is indicative of the 
contributions flanking charges make to the ability of peptide molecules to come together in order 
to elongate a fibril. Both D-Pro-Gly and simple Q26 peptides show similar trends in stability 
when intermolecular repulsion is greater than zero. There is a small, but gradual stabilization of 
fibril structure as repulsion decreases, with both peptide series demonstrating changes in free 
energy of less than 2 kJ/mol. In the D-Pro-Gly series, for the two peptides that have no 
intermolecular repulsion ( and, Figure 4-4), there is a greater stability increase than would 
be expected given the correlation observed for peptides with repulsion. The complexity of this 
relationship between fibril stability and intermolecular repulsion may be indicative of the nature 
of fibril elongation—elongating monomers must dock and arrange themselves to fit a particular 
existing three dimensional lattice. The structural details of this arrangement are still uncertain, 
making it difficult to explain any resulting complexities in energetics.  
Peptide Cr, μM ΔGelong 
(kJ/mol) 
k+ (M-1sec-1) n* log(½ k+2Kn*) Kn* (x10-9)  
K2Q26K2 0.96 -33.98 1.63x103 1.07 -3.15 0.56 
KQ26K3 1.31 -33.20 4.32x102 0.69 -3.05 14 
Q26K 0.66 -34.87 1.03x104 1.01 -1.39 1.4 
KQ26D 0.77 -34.52 *     1.96 3.16 * 
K2Q9PDGQ9K2 2.30 -31.84 1.13x102 0.81 -4.35 7.0 
KQ9PDGQ9K3 2.37 -31.77 5.95x102 0.82 -4.32 1.1 
KQ9PDGQ9K 1.11 -33.63 * 1.82 -2.63 * 
Q9PDGQ9K 1.29 -33.25 2.86x104 1.02 -0.61 0.67 
KQ9PDGQ9D 0.51 -35.51 5.49x104 0.68 0.04 0.74 
K2Q9PDGQ9D2 0.43 -35.95 * 1.57 -0.90 * 
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4.2.3 Fibril Elongation 
Fibril elongation rates can be used as indicators of how a given set of charges affects the ability 
of disordered monomer to encounter and bind to fibril growing ends (docking), and then assume 
the correct structure to allow addition of subsequent monomers (locking) [35, 36]. The fibril 
elongation rate (k+) is a second order elongation rate constant and is defined by a relation 
between two values, k* and [growing ends] (1.3.5.1, 2.2.4, 2.2.5). Table 4-2 contains the 
elongation rates determined for each of the peptides with typical fibril morphology. The 
elongation rates determined for these peptides all lie within the typical range for polyQ peptides 
(102-104 M-1sec-1), and well below the diffusion limited value for protein-protein interactions 
[18, 19, 85, 138]. 
 
Figure 4-5. Elongation rate constant vs. repulsion. 
Elongation kinetics correlations. Illustrates the relationship between the second order elongation rate constant and 
intramolecular (A) and intermolecular (B) repulsion. 
As with ΔGelong, we found that k+ correlates well with intramolecular electrostatic 
repulsion: elongation rates in both peptide series increase as repulsion between the termini 
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decreases (Figure 4-5 A). This indicates that a decrease in repulsion between termini greatly 
enhances a peptide monomer’s ability to encounter and elongate a fibril growing end. Similarly, 
there is a rate constant increase as intermolecular repulsion decreases (Figure 4-5 B). The 
corresponding trends in both inter- and intramolecular repulsions suggest that both 
intermolecular association and folding play important roles in fibril elongation. Enhancement of 
k+ could be due to a number of mechanistic factors: there could be improvements in the rate at 
which monomers encounter fibril ends, the rate at which they stably bind to these ends (dock), 
the rate at which they fold on the fibril surface to reconstitute a new fibril elongation face (lock), 
or any combination of the above. The experiments performed in this work did not allow us to 
determine which combination of steps might be most impacted by terminal charges.  
When the fibril elongation rate constant is compared to fibril stability, these two values 
trend together—as fibril stability increases, the ability of that fibril to elongate also improves 
(Figure 4-6). This correlation is not surprising: ΔGelong is directly related to elongation rate 
through Ka (Cr-1), which is equal to k+/k-. When we consider that these two values were 
determined through entirely different methods, however, the good correlation is indicative of the 
quality of the data acquired by both approaches. 
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Figure 4-6. Elongation rate constant vs. fibril stability. 
Fibril stability, as indicated by ∆Gelong is directly related to elongation rate constant. The more stable a fibril (more 
negative ∆Gelong), the faster it is capable of elongating. 
4.2.4 Application of Nucleated Polymerization Model 
4.2.4.1 Nucleus size determination 
While flanking charges have a demonstrable impact on polyQ fibril stability and elongation, their 
role in a peptide’s ability to initiate fibril formation is still unclear. In an effort to gain some 
insight into this portion of the aggregation mechanism, we have conducted a nucleation analysis 
of all 10 peptides. To this end, the aggregation kinetics of each peptide were measured over a 
range of concentrations, as illustrated for K2Q26K2 in Figure 4-7 (the concentration dependent 
kinetics for the other nine peptides are included in Appendix A). We were then able to apply 
 81 
equations from the Ferrone thermodynamic model of nucleation (2.2.6) to derive essential 
energetic terms describing the nucleation and elongation mechanism of these peptides. The early 
time points of aggregation reactions were graphed versus time2 to yield a straight line, the rate of 
which corresponds to aggregation kinetics as described in Methods. The logs of these time2 rates 
are plotted versus the logs of the initial reaction concentrations to generate a log-log plot (Figure 
4-7 C). The slope of the best fit line to this plot corresponds to n* (equal to n*+2), while the y-
intercept yields a complex parameter (½k+2Kn*) that relates the second order elongation rate 
constants for the nucleus and growing fibril to the nucleation equilibrium constant. 
 
Figure 4-7. Concentration dependent kinetics, time2 and log-log plots of K2Q26K2. 
Time dependent aggregation kinetics for K2Q26K2 (A). From these kinetics, we are able to derive time squared plots 
of the first 20% of each aggregation reaction (B); these initial kinetics are comprised of a combination of fibril 
nucleation and the initial elongation phase. When time squared plots are fit with a best fit line, the rates can be used 
to generate a log-log plot, where the log slope of the time squared fit is plotted vs. the log of the reaction start 
concentration (C). 
 Most of the resulting n* values indicate these peptides aggregate via monomeric nuclei, 
as expected given our intention when designing these peptides (1.4.1.1). Three peptides, 
however, result in an unexpected n*≈2. These peptides, KQ9PDGQ9K, K2Q9PDGQ9D2, and 
KQ26D, also all had atypical morphologies present in the EMs (Figure 4-2). The presence of 
oligomers, protofibrils, or amorphous aggregates alongside fibrillar aggregates in the EM 
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images, combined with the increase in nucleus size in the nucleation analysis together suggest a 
mixture of aggregation mechanisms. All of these peptides with n*≈2 share a common feature of 
low net charge. Two of these peptides have a net charge of -0.2, and the third a net charge of 1.8. 
It is likely that the decrease in solubilizing charge for these peptides plays a role in their ability to 
assume an alternative aggregation mechanism and form non-amyloidogenic aggregates. Worth 
noting is that some other peptides with low net charge (KQ9PDGQ9D and Q9PDGQ9K), 
demonstrate no unusual morphologies or significant changes in n*. So, while net charge does 
impact a peptide’s ability to adopt these alternative mechanisms, low net charge is not a 
guarantee that multiple mechanisms will be present. Unfortunately, we were not capable of 
clarifying why these kinds of subtleties within net charge effects exist in this study. 
 Further support of the hypothesis that multiple mechanisms are in effect for these 
peptides comes from a comparison of high and low concentration reactions. For K2Q9PDGQ9D2, 
EMs of low concentration reaction products no longer showed the atypical aggregate 
morphologies seen in the high concentration reactions, but rather the tape-like morphology 
typically observed for polyQ aggregates. EMs of KQ9PDGQ9K also demonstrate a morphology 
shift as concentration changes from high to low, though uncharacteristic aggregates are still 
present. These combined EM and mechanistic data suggest that the increased n* values seen for 
some peptides reflect the operation of parallel mechanisms, where one (preferred at lower 
concentration) involves typical nucleated growth with n*=1, and the other (favored at high 
concentrations) involves a higher order nucleation mechanism leading to the atypical 
morphologies observed by EM. While this hypothesis suggests that more uniform behavior 
might be obtainable for these low charge peptides by studies at lower concentrations, such low 
concentrations are difficult to study using our existing methods, and so were not considered here. 
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The remaining peptides in this study (with normal morphologies via EM) exhibit n* 
values between 0.6 and 1 (Table 4-2), a typical range for peptides that aggregate via monomeric 
nuclei [18]. 
4.2.4.2  Efficiency of spontaneous aggregation 
The log-log y-intercepts of these 10 peptides, which are equal to log(½ k+2Kn*), range from 3.16 
to -4.35, with more positive values reflecting more favorable aggregation properties (Table 4-2). 
The complex parameter derived from the y-intercept values of the log-log plot (equal to k+2Kn*) 
contains the second order fibril elongation rate and the nucleation equilibrium constant. This 
complex thermodynamic parameter, along with n*, captures the ability of a peptide to undergo 
spontaneous amyloid growth. Our analysis shows that the y-intercept trends with charge 
characteristics in much the same way as elongation rate and fibril stability. The correlations 
between this complex parameter and both inter- and intramolecular repulsion demonstrate that  
 
Figure 4-8. Complex parameter vs. repulsion. 
The trend of the complex parameter linking the elongation rate and Kn* versus the intramolecular (A) and 
intermolecular (B) repulsion of the peptides. 
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the efficiency of nucleation among a series of peptides that all exhibit n*=1, is enhanced by a 
decrease in terminal repulsion (Figure 4-8). This enhancement of fibrillization ability 
corresponds well with the previously described relationships between repulsion and aggregation 
rate or fibril stability. 
4.2.4.3 Nucleus stability calculations yield confusing results 
By using k+ values in conjunction with the y-intercept from the log-log plot, it should be possible 
to calculate the Kn* for each peptide (Table 4-2, Figure 4-9 A and B). These Kn* values are 
extremely similar within each peptide series. Contrary to the known role of charges aiding in β-
hairpin formation, our analysis suggests that the peptides with oppositely charged termini have 
slightly less stable nuclei than do those with repulsion between the termini.  
This counter-intuitive result could be an artifact of the k+ value used to calculate Kn*. 
This rate constant is determined using mature fibril seeds, and the mathematical approach used to 
calculate Kn* assumes that the elongation rate of mature fibrils is identical to that of fibril nuclei 
and early phase aggregates (Figure 1-6). It is possible, however, that terminal charges would 
have a greater impact on elongation of a mature fibril than they would on a fibril nucleus, due to 
the substantial net charge of the fibril and the ease (or difficulty) by which an elongating 
monomer is able to approach the growing fibril. This difference in fibril charge perceived by the 
incoming monomer might prevent k+ for fibrils from matching the elongation rate of the nucleus.  
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Figure 4-9. Kn* vs. repulsion. 
The nucleation equilibrium constant, Kn*, calculated from experimental (A,B) and constant (C, D) k+ values. The Kn* 
values based on experimental measurements show only modest variation (only one order of magnitude between high 
and low values), and no clear trend indicating intra or intermolecular repulsion have an effect on nucleus stability. 
When one fixed elongation rate is used to calculate all Kn* values, a clear trend emerges: the peptides with the least 
amount of repulsion form the most stable nuclei. 
Continuing this train of thought, what happens if we assume that changes in terminal 
flanking sequences and net charge have little to no effect on either of the elongation rates, and 
therefore use a constant k+ for all peptides to calculate Kn* (Figure 4-9C and D)? When 
calculated in this manner, nucleus stability trends as expected, with the hairpin-favoring 
attractive charges forming the most stable nuclei. Though this assumption leads to a pleasing 
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result, it cannot be independently justified. In fact, the trends in Figure 4-6 suggest this 
assumption is not warranted. A more rigorous approach might be to allow k+ for fibrils to vary as 
measured, but to adopt an arbitrarily assigned, constant k+ for nuclei. Inspection of Figure 4-9 
suggests that, at best, this would leave Kn* with some intermediate dependence on charge. 
Because the best approach to calculate Kn* is questionable, we have chosen to keep our 
focus on the complex parameter of k+2Kn* (Figure 4-8), which, along with n*, dictates a 
peptide’s ability to spontaneously form amyloid fibrils. The conclusions reached using this 
parameter are notable, and indicate that net charge and repulsion caused by charged flanking 
sequences play integral roles in polyQ aggregation. 
4.3 DISCUSSION 
These studies have allowed us to develop considerable insight into the qualitative and 
quantitative roles charged flanking sequences play in polyQ peptide aggregation. We hoped to 
answer a series of important questions about polyQ peptide solubility, and paint a picture of the 
role flanking charges might play in fibril structure, stability and aggregation mechanism. The 
results discussed above indicate that charges on the termini have definite impacts on the 
aggregation of polyQ. 
Variations in terminal charge have an unmistakable qualitative effect on aggregation 
mechanism that appears to be related to net charge and its ability to solubilize polyQ. Low net 
charge tends to favor the development of a competing aggregation mechanism featuring an 
increase in nucleus size and leading to the formation of non-fibrillar aggregates. A relationship 
between the onset of this alternative mechanism and the high concentrations necessary for in 
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vitro experiments was suggested by both the increase in n*, and the suppression of these 
mechanisms through decreases in reaction concentration. Whether the alternative mechanisms 
are brought about solely as a result of low net charge, and whether or not uncharged hydrophilic 
residues would discourage these mechanisms as effectually as charged residues, are still unclear. 
Reactions conducted in varying reaction conditions that result in a neutralization of net charge 
(Appendix A.2) further support the idea that neutralization of net charge can impact the 
aggregation of these peptides. However, this modification to aggregation behavior and our 
resulting inability to predict the exact performance of a peptide with charged flanking residues 
justifies our decision to be selective in the choice of flanking sequences and core peptides. The 
judicious selection of core polyQ peptides allowed for the generation of data that could be more 
easily interpreted and has led to a better understanding of how short amino acid sequences 
impact polyQ aggregation. 
 The quantitative impacts of terminal charged residues trended exactly as we might have 
expected considering their known ability to affect β-hairpin closure on other peptides, along with 
their roles in general intermolecular interactions. Energetic effects on polyQ fibril formation 
were relatively minor, with a maximal stability enhancement of approximately 10% when 
comparing the ΔGelong values. Elongation rate also trends well with decreases in repulsion. 
Variation in elongation rate is greatest for the D-Pro-Gly, β-hairpin mimetic series of peptides, 
which demonstrate increases in k+ of 2-3 orders of magnitude as repulsion decreases. Simple 
polyQ peptide elongation rates vary less, with the greatest k+ value only an order of magnitude 
higher than the lowest. The lesser impact on elongation rate for the simple polyQ peptides is 
likely more representative of the role flanking charges may have on disease polyQ proteins. 
Since disease polyQ proteins are longer and lack β-hairpin enhancing motifs, we might expect 
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further minimization in flanking sequence effects than those observed in the simple polyQ 
peptide. In any case, flanking sequences in general in disease proteins do not feature large 
collections of charged residues immediately neighboring the polyQ sequence. 
 Flanking charges are clearly important to aggregation mechanism and elongation, but 
what about nucleation? Unfortunately, any quantitative trends are lost when we calculate Kn*: the 
resulting values have no discernible trend with net charge or repulsion. These calculated values 
may be accurate representations of the nucleation efficiency of these peptides. However, it is 
more likely that the standard assumption that elongation rates of nuclei are comparable to those 
measured for mature fibrils is flawed, as least when used to dissect charge effects, and 
contributed to these unexpected results. While this assumption may have little impact when 
comparing Kn* values across a single flanking charge sequence (such as the K2-K2 flanking 
residues traditionally used in polyQ studies), variation of net charge and repulsion due to 
modification of flanking charges could result in substantial changes in k+ as compared to k+n* 
(Figure 1-6). The lack of a clearly defined relationship between elongation rates as terminal 
charge varies could explain our unexpected results for Kn*, and suggests that any significant 
conclusions should not be based these data without further investigation.  
In spite of the challenges in deciphering the nucleation equilibrium constants, the 
complex parameter, k+2Kn*, is still interpretable, and confirms that, in cases where n* is constant, 
spontaneous aggregation efficiency improves with decreasing repulsion. The changes in this 
complex parameter are greater for the β-hairpin encouraging series than the simple polyQ 
peptides, again validating the design of our model peptide series and confirming the important 
impact that chain flexibility has on modulating charge effects on elongation and nucleation. 
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While charged flanking sequences clearly have an impact on the aggregation of polyQ 
peptides, this study demonstrates that our approach of adding two Lys residues to each polyQ 
terminus (K2-K2 peptides) is a valid choice for the study of simple polyQ aggregation. This 
flanking sequence resulted in aggregation via a homogeneous monomeric nucleated 
polymerization mechanism, and led to the formation of fibrils with typical morphologies (as 
observed by EM). The use of a single, consistent flanking sequence across peptide studies also 
means that it is possible to compare Kn* values for all of these peptides, an important comparison 
to make when considering the impact of variations in the polyQ sequence on the aggregation 
mechanism. 
How do these conclusions now translate to our understanding of polyQ in disease? These 
results make it clear that even a difference as small as 4 to the net charge of a peptide is capable 
of having a meaningful effect on aggregation, with notable effects on the fibril stability and 
elongation characteristics of a given peptide. However, our ability to translate these conclusions 
to the impact longer flanking sequences have on polyQ aggregation in disease is still limited. 
One takeaway may be that regardless of the flanking sequence, it must contain enough 
solubilizing charge to allow the polyQ sequence to remain soluble until amyloid formation is 
initiated. The 17 and 29-amino acid N-terminal flanking sequences of synthetic huntingtin exon 
1 and AT7 model peptides have net charges of +1.5. Both of these peptides aggregate cleanly to 
form homogeneous amyloid, indicating that the small net charge imparted by these N-terminal 
fragments is clearly sufficient to prevent precipitous, disordered aggregation. It is worth noting 
that polyQ disease proteins have flanking sequences with a variety of charge densities and amino 
acids types.  In addition, it is not clear how to think about the “solubilizing effect” of flanking 
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sequence on polyQ, when the flanking sequences are long sequences encompassing many 
domains and many types of sequences.   
While flanking charged residues clearly play an important role in the aggregation of 
polyQ peptides, their contributions do not encompass the entire role flanking sequences have in 
the aggregation of polyQ disease proteins. Thus, while polyQ with AT7 flanking sequences 
maintains the simple polyQ aggregation mechanism [18], the critical early state of the 
aggregation mechanism of polyQ with htt-exon 1 flanking sequences is dominated by initial α-
helix formation and interactions between the N-termini [96]. In spite of such complications, the 
similarity in aggregation properties across terminal charge mutations found here further justifies 
our application of simple polyQ aggregation studies to amyloid formation in disease, since there 
is a well-defined dominating mechanism. Thus, even with disease proteins where flanking 
sequence imposes more elaborate, multi-step nucleation mechanisms, it appears—for example 
judging by repeat length dependence—that the fundamental polyQ aggregation mechanism and 
its sequence constraints continue to contribute to the overall mechanism [139]. 
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5.0  REPEAT LENGTH DEPENDENT EFFECTS ON POLYQ AGGREGATION 
5.1 OVERVIEW 
Though it is well known that Gln repeat length plays an important role in amyloid nucleation 
[18] and that aggregation rate increases with repeat length [64, 74], little is known about the 
details of how additional glutamines contribute to fibril stability and the kinetics of fibril 
formation. By applying a nucleated polymerization model of amyloid formation [22] to the 
aggregation kinetics of polyQ peptides with a range of repeat lengths, it was possible to 
determine the role repeat length trends play in polyQ amyloidogenesis. 
 A series of polyQ peptides were chosen over a range of repeat lengths, and their 
aggregation kinetics and fibril stability were investigated (Table 5-1). Most peptides examined 
here lie above the monomeric nucleation threshold of 24-26 Glns (1.3.4), but two peptides that 
aggregate via tetrameric nuclei were also considered in an effort to provide some insight into the 
reason we observe this repeat length dependent shift in nucleus structure. 
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Table 5-1. Repeat length peptides and features. 
Peptide Sequence n*  log (1/2 k+2Kn*)a Cr (Molar) ΔGelong (kJ/mol) 
K2Q18K2 3.7b 2.71 3.65E-6c -32.27 
K2Q23K2 3.9b 6.77 3E-6c -32.78 
K2Q26K2 1.04 0.9b -3.15 -3.33  9.6E-7 -35.71 
K2Q27K2 1.22 0.9b -3.63 -3.08  8.4E-7 -36.19 
K2Q29K2 0.79 -2.48    
K2Q30K2 0.66 -2.8    
K2Q31K2   8E-7 -36.19 
K2Q34K2 0.96 -1.68    
K2Q37K2 0.90 -2.09    
K2Q42K2 0.53 -0.92  3.5E-7 -38.33 
K2Q47K2 0.87d -0.22   
a Calculated for all peptides except Q18 and Q23 with n*≡1. b From [18]. c Personal communication from KK. d From 
[85]. 
5.2  RESULTS 
5.2.1 Fibril stability 
Cr was determined for each peptide as described previously (2.1.5). Comparisons of these values 
(Table 5-1) and their corresponding ΔGelong indicate a clear link between fibril stability and 
increasing repeat length (Figure 5-1). There is a notable enhancement of stability as the repeat 
length threshold between tetrameric and monomeric nuclei is crossed near Q25. Beyond this 
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threshold, the fibril continues to stabilize with increasing Gln length, but less and less with each 
subsequent Gln addition. 
 The differences in free energy of elongation across the transition from tetrameric nucleus 
to monomer, between Q23 to Q26, are not insignificant. ΔΔGelong between these two peptides is 
2.9 kJ/mol: an increase in stability of nearly 10% for an addition of only 3 residues, or nearly one 
kJ/mol per residue. While the ΔΔGelong between Q26 (the shortest monomeric nucleating polyQ 
peptide) and Q42 is comparable at 2.97 kJ/mol, it occurs over a span of 16 Glns, for an 
incremental increase of less than 0.2 kJ/mol per residue. These data trends suggest the possibility 
of a structural connection between the fibril stability trends and the switchover in nucleus size. 
 
Figure 5-1. ∆Gelong versus repeat length. 
As Gln content of a polyQ peptide increases, so does fibril stability as indicated by ΔGelong. There is a notable jump 
in stability near Q25, suggesting aggregation through a monomeric nucleus results in a fibril 10% more stable than a 
fibril formed through tetrameric nucleus. 
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5.2.2 Spontaneous aggregation and nucleation 
Aggregation mechanism and kinetics were investigated for all peptides by applying the Ferrone 
model of nucleated polymerization [22] (2.2.6). Aggregation kinetics were followed for a given 
peptide at a range of concentrations (shown for Q42 in Figure 5-2 A), and the mathematical 
model was then applied to these data to generate time2 (Figure 5-2 B) and log-log plots (Figure 
5-2 C), as described (2.2.6) (data for other peptides is shown in Appendix section A.3). Nucleus 
size (n*) was determined from the best fit line of the log-log plot. The y-intercept, a complex 
parameter which is defined by k+ and Kn*, was extrapolated based on a fit line with the slope 
fixed to 3, corresponding to n*=1 (Table 5-1). Fixing the slope to an integer value in this manner 
minimized the impact of experimental variability in fractional values of n* on the derived y-
intercepts. The best fit line of a log-log plot corresponding to a monomeric nucleus often yields a 
slope slightly less than 3 (fits slope of 2.6-3.1 can still correspond to monomeric nuclei), and this 
variation is entirely consistent with experimental discrepancies rather than an actual mechanistic 
effects that might lead to a fractional n* [18].  
 
Figure 5-2. Q42 kinetics, time2 and log-log plots. 
In order to investigate the contributions of repeat length to nucleus stability and 
elongation rates (Kn* and k+), the log-log y-intercept values, equal to log(½k+2Kn*), were plotted 
 95 
versus Gln repeat length for peptides with n*=1 (Figure 5-3). This complex parameter 
corresponds to the ability of a given peptide with n*=1 to undergo spontaneous aggregation. 
These y-intercepts exhibit what appears to be a non-linear, possibly exponential trend with repeat 
length for polyQ peptides with monomeric nuclei. This trend is qualitatively similar to that of 
ΔGelong with repeat length. This suggests that peptides with the most stable end stage fibrils are 
also more favored to spontaneously nucleate and elongate to form these structures.  
 
Figure 5-3. A fit of y-intercept versus repeat length for peptides with monomeric nuclei 
The log-log y-intercepts, equal to log(½k+2Kn*), of peptides with a monomeric nucleus (n*=1) as calculated from 
both new experiments (■) and previously published data (▲,), trend well with repeat length. The fit line is the 
best fit of the all data, both previously published and acquired for this study. 
Unfortunately, this dataset and its fit leave much to be desired. If it is accurate at polyQ 
repeat lengths lower than Q26, the fit indicates that Q23 should aggregate via a monomeric 
nucleus with only a modest drop-off in efficiency when compared to Q26 (as determined by the 
log(½k+2Kn*) value of the fit at these repeat lengths). As discussed, previous studies 
demonstrated that Q23 aggregates via a tetrameric nucleus [18]. However, the fit from Figure 5-3 
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suggests that we should have observed aggregation of Q23 via a monomeric nucleus in the 
reactions previously studied experimentally (located in the grey shaded region in Figure 5-4 A). 
This conclusion can be reached by examining the plots in Figure 5-4, which were generated by 
first plotting the actual experimental data (from [18]) for K2Q18K2 and K2Q23K2 in a log-log plot 
(experimental points plotted with their best fit line in solid black). In Figure 5-4 A, the log-log 
line for a monomeric nucleus (slope = 3) with the y-intercept predicted for K2Q23K2 by the fit in 
Figure 5-3 (solid teal line) shows that the expected aggregation rates for this peptide at the 
concentrations tested in lab would have been faster than those observed experimentally.  
 
Figure 5-4. Calculation of monomeric y-intercepts for short polyQ peptides. 
Experimental log-log plots of Q23 (○) (A, B) and Q18 (■) (B) and their best fit lines (solid black). The theoretical log-
log plot based on the fit in Figure 5-3 is shown in teal in (A). When compared to the experimental data, this line 
indicates experiments should have measured a monomeric nucleus, rather than the tetramer, actually observed. 
When a hypothetical fit for n*=1, slope=3, (dashed line) is fit through the lowest concentration point of each of 
these data, a maximal y-intercept can be extrapolated (B, blue dashed line in A). It is also possible that the 
spontaneous aggregation efficiency of these peptides through a monomeric nucleus is lower than that indicated by 
our maximal y-intercept. This would result in log-log fit lines lower than the one approximated here (for example, 
black dotted lines) (A). 
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The most likely explanation for why aggregation via a monomeric nucleus was not 
observed is that the y-intercept value for monomeric nucleation by Q23 is overestimated in the 
Figure 5-3 fit. We do believe it is possible, under the right conditions, for some of these short 
peptides to achieve monomeric nuclei; they are simply less energetically favored than the 
tetrameric nucleus under the experimental conditions by which they have been studied (if there 
are enough residues to form a β-hairpin structure, aggregation via this structure as a monomeric 
nucleus should be possible). In an effort to gain a better understanding of the conditions 
necessary to achieve a monomeric nucleus for peptides with repeat lengths below the Q25 
threshold, we generated theoretical monomeric log-log plots for Q23 and Q18 based on previous 
experimental data (Figure 5-4). The effects of various theoretical y-intercept values on the 
concentration dependence of aggregation via a monomeric nucleus were investigated by drawing 
lines with slopes of 3 (i.e., for n*=1) originating at various y-intercepts. By forcing one of these 
lines through the point corresponding to the lowest peptide concentration studied (the 
concentrations at which monomeric nuclei are favored must be lower than the lowest 
concentration point that fits the n*≈4 line, otherwise aggregation via a monomeric nucleus would 
occur at a faster rate than aggregation via a tetramer) we have generated log-log fits that produce 
maximal y-intercept values for a monomeric nucleus within each of these peptides (e.g. blue 
dashed line in Figure 5-4 A). The difference in the rates of the tetrameric nucleus and the 
monomeric nucleus with maximal y-intercept are illustrated by double sided arrows in Figure 
5-4 A. It is possible (and even likely) that these low experimental concentrations are significantly 
higher than the actual concentration at which a monomeric nucleus could be favored, so (if a 
monomeric nucleus does exist for these peptides) the actual log-log fit would be a line of slope 
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three that is no higher than those plotted in Figure 5-4 B (as illustrated for Q23 by the black 
dashed or dotted lines in Figure 5-4 A). 
When these theoretical y-intercept upper limits are added to the plot of log(½k+2Kn*) 
versus Gln repeat length (● and ○ in Figure 5-5), and the fit is forced through the Q23 point, the 
exponential trend from Figure 5-3 becomes more defined. This new fit indicates removal of 
additional Gln residues results in notable decreases in the ability of a polyQ peptide to 
spontaneously aggregate through a monomeric nucleus. Thus, Q23 and Q18 are not observed to 
aggregate via monomeric nuclei because of the steep drop in nucleation efficiency in the range of 
Q25, and the existence of a competing tetrameric nucleus pathway.  
In fact, the change in y-intercept per residue (Δy-int/res) increases rapidly at repeat 
lengths lower than 25 (Figure 5-6), and suggests the actual Q18 y-intercept is likely to be 
significantly lower than the approximated maximum from Figure 5-4. According to this fit, Q18 
peptides favor a monomeric nucleus at concentrations less than 177 μM—a reaction start 
concentration nearly 3 times lower than the lowest concentration previously studied [18]. Any 
reactions conducted at these concentrations would be extremely slow due to their inefficient 
aggregation ability. The lowest concentration followed thus far, 580 μM, has a t1/2 of 
approximately 200 hours; decreasing the concentration by a factor of 3 would only further slow 
the kinetics, making it extremely difficult to observe any aggregation. 
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Figure 5-5. New fit of y-intercept vs. repeat length for peptides with monomeric nuclei 
When an exponential fit for all shaded data points is forced through the projected Q23 y-intercept value (●), we 
generate a fit that appears to match the efficiencies of aggregation of various polyQ peptides as they aggregate 
through monomeric nuclei. 
While this new fit is very convenient, and it explains nicely why we do not see 
monomeric nuclei for short polyQ lengths, it is purely conjectural. It would be ideal if we could 
somehow test whether this fit is a valid predictor of the y-intercept for short polyQ peptides. We 
have previously discussed the experiments conducted with two short D-Pro-Gly peptides, 
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Figure 5-6. Δy-int/residue versus repeat length. 
When tangents from the fit line from Figure 5-5 are used to calculate Δy-int/res, we find the y-intercept changes 
more per residue for short polyQ peptides, indicating that removal of a single Gln in short peptides has a greater 
impact on aggregation ability than on long peptides.  
K2Q9PDGQ9K2 and K2Q10PDGQ10K2, which have n*=1 (1.4.1.1). Conveniently, the experimental 
log-log plots of these hairpin peptides can be used to generate a Δy-int/res values that can be 
used to test the reasonableness of the fit in Figure 5-5. The Δy-intercept between these Q20 and 
Q22 analog peptides is 0.98, which corresponds to a Δy-int/res of 0.49 for a Q21 peptide. As can 
be seen in Figure 5-6, Δy-int/res from the Figure 5-5 fit varies along polyQ repeat length from 
~0.1 to ~0.7 (for repeat lengths that have been studied experimentally). According to this figure, 
the theoretical Δy-int/res of Q21 is 0.53, an excellent match to the experimental value determined 
from the hairpin peptides. This consistency between Δy-int/res values indicates the fit line in 
Figure 5-5 is actually a fairly realistic approximation of the y-intercept of polyQ peptides, 
validating our approach. The steepness of the Δy-int/res plot in this repeat length range helps 
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explain the very sharp transition in experimental n* values and ultimate mechanism change at 
low repeat length. 
5.2.3 Elongation rates and nucleation equilibrium constants 
The elongation rate, k+, for each peptide was determined using k* and [growing ends] values 
from seeded elongation reactions and growing ends titration assays, as described (2.2.4, 2.2.5). 
The resulting elongation rates are plotted in Figure 5-7. These k+ values vary significantly more 
than expected given the similarities in previously reported polyQ k+ values [18, 85]. These new 
k+ values have no clear trend with polyQ length, and in fact appear to vary periodically as repeat 
length increases.  
 According to the Ferrone equation, the k+ values and the log-log y-intercepts can be used 
in conjunction to determine the Kn* for these peptides (Figure 5-8). In spite of the large variation 
in k+, the Kn* values still demonstrate a rough correlation with polyQ repeat length. As the 
number of Gln residues increases, Kn* also increases, demonstrating that, as might be expected, 
addition of Gln residues improves the stability of the monomeric nucleus structure. 
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Figure 5-7. k+ versus repeat length. 
Elongation rate varies significantly over the polyQ peptides studied, and has no clear trend with repeat length. 
 
 
Figure 5-8. Kn* versus repeat length. 
Nucleus stability as indicated by Kn* increases with Gln content. Significant changes in Kn* occur when repeat 
length is in the mid-thirties, consistent with disease threshold length. 
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5.3 DISCUSSION 
We investigated a series of polyQ peptides across a range of repeat lengths (Q18-Q42) to 
determine the resulting trends in fibril stability, elongation ability, and nucleation. The data 
confirm that addition of Gln residues increases fibril and nucleus stability, as previously posited 
[74]. More interestingly, the number of Gln residues in a polyQ sequence has a predictable effect 
on these terms, which allows for the estimation of kinetics parameters and thermodynamic values 
for polyQ repeat lengths that have not been measured.  
All three terms with values that corresponded well with Gln repeat length (ΔGelong, y-
intercept, and Kn*) have transition points, or repeat length thresholds that indicate subsequent 
increases in Gln content result in only minor variations in their value. For ΔGelong, this threshold 
corresponds well with the threshold for nucleus size, in the mid-twenties. This suggests that there 
exists some factor that is common to both formation of a stable monomeric nucleus and fibril 
stability, possibly the ability to favorably fold into a β-hairpin structure. The log-log y-intercepts 
described in this chapter indicate the efficiency with which a given polyQ can spontaneously 
aggregate through a monomeric nucleus. This efficiency appears to increase less markedly once 
repeat length enters the 30’s (Figure 5-6). This correspondence to pathogenic repeat length 
indicates that enhancement of a polyQ sequence’s aggregation ability beyond its capacity to form 
a monomeric nucleus may play a key role in the threshold of disease. 
For the first time, it has been possible to confirm the feasibility of monomeric nuclei in 
peptides that experimentally exhibit multimeric nuclei, such as Q18 and Q23. For these peptides, 
monomeric nuclei are demonstrated to be favored in low concentration reactions that aggregate 
extremely slowly, because they are so inefficient at aggregation (as indicated by their low y-
intercepts): Q23 peptides favor a monomeric nucleus at concentrations of 100 μM or less, while 
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Q18 aggregates via a monomeric nucleus when reaction concentration is less than 177 μM. By 
decreasing the likelihood for multiple molecules to associate (through decreases in 
concentration), aggregation through a tetrameric nucleus becomes a less favored mechanism. 
The point at which this switch in mechanism occurs is representative of a concentration 
dependent energetic transition. 
In contrast with clear trends in ΔGelong, Kn* and the log-log y-intercept, k+ does not follow 
a pattern with increasing Gln repeat length. In fact, k+ even appears to oscillate as repeat length 
increases from Q26 to Q42. This variation in the elongation rate constant may indicate subtle, and 
previously unobserved, repeat length effects on the manner in which polyQ peptides are able to 
complete the dock-and-lock mechanism of elongation. For example, the width of the β-strand 
may play an important role in elongation—if a peptide is too long or short to easily form β-
strands of the ideal length, it may take longer to undergo the “locking” step of aggregation and 
have a decrease k+ compared to other peptides of similar length (such as Q37 in Figure 5-7) 
Continued improvements in nucleus and fibril stability beyond the disease threshold are 
consistent with the decrease in age of onset and more rapid deterioration of patients with longer 
polyQ repeat lengths, a trend that continues well above the repeat length threshold [41] (1.2.1). 
The results presented in this chapter suggest that the ability of a polyQ expansion to stably form 
and aggregate efficiently through a monomeric nucleus plays an important role not only in fibril 
stability, but also in disease initiation and progression. 
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6.0  CONCLUSIONS 
6.1 THESIS CONTRIBUTIONS 
When this work was first begun, the lab had just confirmed a β-hairpin structure as a likely 
candidate for the monomeric nucleus observed in aggregation of polyQ peptides of 26 Glns or 
more. As the polyQ aggregation mechanism was developed, questions arose regarding the 
contributions of portions of the primary polypeptide sequence to the energetics of this reaction 
[122] and the validity of our proposed mechanism indicating polyQ aggregates via a 
homogeneous nucleated growth polymerization mechanism with a monomeric nucleus and 
monomer addition [120]. The intent of this work was to gain more specific information regarding 
the roles of terminal charge and additional Gln residues in the aggregation mechanism of simple 
polyQ peptides. 
6.1.1 Use of growing ends titration assay 
The experiments conducted in Chapter 3.0 indicate that the growing ends titration assay most 
likely functions through the detection of one added label of many incorporated onto the 
elongation site of a growing fibril. More specifically, we believe the terminal biotinyl-polyQ 
incorporated into a fibril maintains a biotin accessible to solution and labeled streptavidin, while 
internal biotins are somehow sequestered and not detectable. 
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When we used the results from this assay in Chapter 4.0 to determine Kn* (4.2.4.3), the 
resulting values were surprising and counterintuitive. This may speak to limitations of the 
approach set forth in Ferrone’s original mathematical model, in which he equates the elongation 
rate of the nucleus to that of the fibril (discussed in 1.3.5.1). While the assumptions used to set 
this equality may apply in cases where n* is equal to some large multimer, they may not hold 
true when the electrostatic ‘appearance’ of a fibril to an incoming monomer is much different 
than that of the monomeric nucleus (which is likely the case for many of the peptides studied in 
Chapter 4.0 ). Therefore, while the growing ends titration may lead to a reasonable value for 
fibril elongation rate (k+) we cannot always use this value coupled with Ferrone’s equations to 
determine nucleus stability. On the other hand, it seems likely that any discrepancies caused by 
the use of the k+ value for both equilibrium constants are minimized when comparing peptides 
with nearly identical electrostatics (i.e. K2Q27K2 versus K2Q9PDGQ9K2), because their Kn* 
values, if biased at all, will be biased by the same factor (the ratio between k+n* and k+). This 
effect does make it difficult to compare Kn* across variably charged peptides, making our ability 
to interpret terms such as the complex parameter describing spontaneous aggregation ability (that 
is, the y-intercept of the log-log plot) all the more important. 
6.1.2 Terminal charge contributions 
Application of a model for homogeneous nucleated polymerization to the aggregation kinetics of 
polyQ peptides with varying terminal charges allowed us to parse out the contributions these 
charges have on the aggregation of polyQ peptides. The results suggest that solubility of the 
polyQ containing molecule is important to its ability to aggregate via a single nucleated 
polymerization mechanism—when solubility is decreased because of insufficient net charge, a 
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competing mechanism developed, resulting in the appearance of non-amyloidogenic 
morphologies via EM and an increase in nucleus size. 
Among those polyQ sequences examined that exhibit homogeneous amyloid formation 
mechanisms and products, terminal charges also play an important role in a polyQ peptide’s 
ability to spontaneously aggregate. The lower the amounts of inter- and intra-molecular repulsion 
(and/or the greater the amount of attraction), the more efficiently a peptide is able to 
spontaneously aggregate, and the more stable the resulting fibril. These trends suggest that the 
abilities to fold into a stable hairpin (bringing termini close together), as well as bimolecularly 
associate to elongate fibrils play similar and important roles in polyQ fibril formation. 
This chapter also further validates our hypothesis that polyQ aggregates via a monomeric 
nucleus (for repeat lengths above a certain number) and elongates through monomer addition. 
Our ability to detect the presence of oligomeric and non-amyloid species in reactions of peptides 
with low net charge, both visually by EM and through application of our thermodynamic model, 
suggests that we have the general capability to identify them if and when they are involved in 
aggregation mechanisms. The lab’s earlier work investigating the detailed mechanism of simple 
polyQ aggregation used multiple methods that together ruled out the presence of oligomers at the 
start and during the reaction (DLS in particular, but also 20 nm filtration tests and EM) [18]. 
Thus, we can say that under certain conditions (such as a decrease in net charge) simple polyQ 
peptides are capable of forming non-amyloid oligomers as end products of the aggregation 
reaction, however, they are not the bulk of the reaction product, and can usually be eliminated by 
decreasing reaction concentration. They also are not confirmed to be intermediates in the 
aggregation of polyQ amyloid, but may be the end stage product of aggregation via a separate 
mechanism, as indicated by the composite n* values, and their presence in end stage reactions. 
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In general, the effects of charged flanking sequences trend well with what might be 
expected based on our proposed mechanism of aggregation for simple polyQ peptides. The role 
such charge effects might have when incorporated to longer flanking sequences (such as those in 
disease proteins) is still unclear, and requires future study. However, this work clearly indicates 
that flanking sequences can have unmistakable effects on polyQ aggregation. 
6.1.3 PolyQ repeat length 
The same approach was applied to a series of different repeat length polyQ peptides to further 
investigate the kinetic and thermodynamic components to polyQ repeat length thresholds 
observed in in vitro aggregation and in vivo pathogenesis. The resulting trends in fibril and 
nucleus stability, and in spontaneous aggregation ability, indicate that all of these terms 
experience enhancement with addition of Gln residues up to and through the pathological 
threshold range.  
The mechanistic transition from a tetrameric to monomeric nucleus between Q23 and Q26 
previously suggested a possible contributing factor to the biophysical basis for disease thresholds 
[18]. An extrapolation of aggregation ability (as indicated by the log-log y-intercept) of polyQ 
peptides with monomeric nuclei suggests that the transition between monomeric and multimeric 
nuclei exists at the intersection of two trend lines, each indicative of its own aggregation 
mechanism/nucleus size, that describe the concentration dependence of the energetics of the 
aggregation mechanism. Thus, there appears to be no intrinsic barrier to nucleation of amyloid 
formation via a monomeric nucleus for K2Q23K2 peptides in the experimentally accessible 
concentration range, but the mechanism is not observed because nucleation via a tetrameric 
nucleus is more favorable at these concentrations.  A major contribution to this situation appears 
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to be a rather dramatic reduction in nucleation efficiency (as reported by y-intercepts) as repeat 
length decreases through the Q26 to Q18 range. 
This large drop in nucleation efficiency is further support for a β-hairpin as the nucleus 
structure: as repeat length decreases in this range, each subsequent removal of a Gln that could 
contribute to hydrogen bonding leads to a larger and larger losses in stabilization of the hairpin 
nucleus, corresponding to larger and larger decreases in y-intercept. 
Thus, even among polyQ sequences that share a unitary value for n*, further lengthening 
of the polyQ repeat lengths leads to further improvements in a polyQ peptide’s ability to 
spontaneously aggregate and stabilize amyloid fibrils. Both of these energetic consequences 
exhibit transition points at or near the pathological disease threshold, suggesting that the 
aggregation properties of polyQ peptides beyond this transition point are likely contributors to 
the disease state. 
6.1.4 Summary 
The results of these studies indicate that mutations in polyQ sequences that enhance their ability 
to both form β-hairpins and associate (whether by increases in repeat length or attraction) 
facilitate polyQ aggregation through a fibrillization pathway with a monomeric nucleus. In 
general, fibril stability corresponds well with spontaneous aggregation ability. These results 
could have implications for polyQ in disease—any mutation that enhances amyloid formation 
could result in a decrease in repeat length threshold or enhanced pathogenicity. For example, the 
SCA6 low repeat length threshold (Table 1-1) could be a result of enhancements to aggregation 
ability caused by β-hairpin stabilizing effects of the flanking sequences.  
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6.2 FUTURE DIRECTIONS 
6.2.1 Does peptide net charge or solubility have a greater impact on mechanism? 
Results described in 4.2.4.1 suggest that low net charge on simple polyQ peptides may introduce 
a preference for an alternative aggregation mechanism. Experiments could be conducted to 
confirm this hypothesis. One approach would be to use hydrophilic, but uncharged residues in an 
effort to provide solubility to the polyQ even in the absence of formal charges. The use of Ser or 
Thr, both relatively polar, uncharged residues, may aid enough in solubilizing the polyQ enough 
to allow monitoring of the aggregation kinetics. If these residues sufficiently solubilize polyQ 
sequences, concentration dependent kinetics could be measured, allowing for the confirmation 
(or contradiction) of the hypothesis that low net charge is a contributor to the assumption of 
alternative aggregation mechanisms. 
6.2.2 Can we generate a monomeric nucleus from low repeat length peptides? 
The data presented in 5.2.2 suggests that Q23 should aggregate via a monomeric nucleus at low 
concentrations. If this is true, it should be possible to confirm by conducting reactions at the low 
concentrations hypothesized to generate an n*=1 for peptides shorter than Q25. These 
experiments have not been conducted up to this point because the low concentrations necessary 
for their success are time prohibitive. In addition, because of the very long incubation times 
required and relatively low aggregation extents expected, it is not clear that data of sufficient 
quantity can be obtained, even if one is willing to devote the necessary time and material to the 
experiment. As experimental methods continue to develop, our ability to accurately follow the 
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kinetics of these long time course reactions without the need for excessive material may 
improve. The successful generation of an experimental log-log plot for peptides of repeat lengths 
of Q23 or lower, similar the simulated plots described in Chapter 5.0 would confirm our 
conclusion that short repeat length polyQ peptides are capable of accessing a monomeric nucleus 
whose formation and/or elongation, however are energetically unfavorable. 
6.2.3 Big picture 
While these studies have led to a clearer understanding of the kinetics and thermodynamics of 
aggregation in models of simple polyQ, it is still unclear how this mechanism translates to the 
aggregation of disease relevant peptides or proteins. Flanking sequences clearly have an impact 
on aggregation mechanism, whether by introduction of an alternative mechanism or 
enhancement of the existing one. To better evaluate whether differences in pathogenicity across 
polyQ disorders can be attributed to aggregation propensities, systematic studies of all disease 
relevant flanking sequences should be conducted. This work has already been begun by our lab 
with HttNT and AT7 model peptides. By investigating other disease model peptides we might 
gain further insight into the changes in aggregation mechanism caused by longer flanking 
sequences, as well as the degree to which mechanistic details learned from simple polyQ 
peptides might be also relevant to disease protein aggregation. 
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APPENDIX A 
SUPPLEMENTARY DATA 
A.1 COMPLETE KINETICS DATA FOR TERMINAL CHARGE PEPTIDES 
The kinetics, time2 and log-log plots for the nine terminal charge peptides not shown in Chapter 
4.0 , Section 4.2.4.1. For all peptides, kinetic traces are shown in (A), the time2 plots for the early 
phase kinetics in (B), and the resulting log-log plots in (C). Only peptides with good fits (R2≥0.7) 
to the time2 plot were used in log-log plots. 
 
Figure A-1. KQ26K3 kinetics, time2, and log-log plot. 
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Figure A-2. Q26K kinetics, time2, and log-log plot. 
 
Figure A-3. KQ26D kinetics, time2, and log-log plot. 
 
Figure A-4. K2Q9PDGQ9K2 kinetics, time2, and log-log plot. 
 114 
 
Figure A-5. KQ9PDGQ9K3 kinetics, time2, and log-log plot. 
 
Figure A-6. K Q9PDGQ9K kinetics, time2, and log-log plot. 
 
Figure A-7. Q9PDGQ9K kinetics, time2, and log-log plot. 
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Figure A-8. KQ9PDGQ9D kinetics, time2, and log-log plot. 
 
Figure A-9. K2Q9PDGQ9D2 kinetics, time2, and log-log plot. 
A.2 REACTION CONDITIONS’ ROLE IN AGGREGATION 
K2Q9PDGQ9K2 was investigated under a range of reaction conditions including varied pH, salt 
(NaCl) concentration, and temperature in an effort to determine the role they had on aggregation. 
The kinetics of these reactions are shown in Figure A-10. 
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Figure A-10. Reactions of K2Q9PDGQ9K2 at various pH, salt concentrations, and temperatures. 
 As pH is shifted from acidic to basic, aggregation rate of K2Q9PDGQ9K2 increases. The pI 
of this peptide is 10.48, so this enhancement of aggregation rate may correspond to a decrease in 
net charge of the molecule as it approaches the pH at which it will bear no charge. There is still a 
lag phase present at the beginning of the reaction, even at pH 9, suggesting that the decrease in 
net charge has not resulted in a complete loss of solubility. No concentration dependence was 
measured for any of these variable reaction conditions, so it is not clear whether neutralization of 
the K2Q9PDGQ9K2 net charge had any effect on aggregation mechanism, as with other peptides 
with no net charge described in Chapter 4.0 . Consistent with the results in that chapter, a 
decrease in repulsion does correspond in an increase in aggregation rate, suggesting an 
enhancement in β-hairpin formation and fibril elongation as pH is increased. 
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 High ionic concentrations would be expected to have a screening effect on charged 
regions of K2Q9PDGQ9K2. Figure A-10 C demonstrates that increases in salt concentration 
(NaCl, specifically) results in enhancement of aggregation rates, again suggesting that decreases 
in repulsion encourage spontaneous aggregation. 
 Finally, reactions at different temperatures also demonstrate differences in aggregation 
rates. These differences are subtle, but low temperatures appear to enhance aggregation kinetics. 
This trend is not due to any change in perceived charge, and has been observed previously. 
A.3 COMPLETE KINETICS DATA FOR VARIABLE REPEAT POLYQ 
The kinetics, time2 and log-log plots for the variable repeat length peptides not shown in Chapter 
5.0 , Section 5.2.2. For all peptides, kinetic traces are shown in (A), the time2 plots for the early 
phase kinetics in (B), and the resulting log-log plots in (C). Only peptides with good fits (R2≥0.7) 
to the time2 plot were used in log-log plots. 
 
Figure A-11. K2Q27K2 kinetics, time2, and log-log plot. 
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Figure A-12. K2Q29K2 kinetics, time2, and log-log plot. 
 
Figure A-13. K2Q30K2 kinetics, time2, and log-log plot. 
 
Figure A-14. K2Q34K2 kinetics, time2, and log-log plot. 
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Figure A-15. K2Q37K2 kinetics, time2, and log-log plot. 
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